Establishment of serum ELISA tests against putative lung adenocarcinoma antigens by Stöger, Verena Anna-Maria
 1 
 
 
 
 
DIPLOMARBEIT 
 
 
 
Titel der Diplomarbeit 
„Establishment of Serum ELISA Tests 
against Putative Lung Adenocarcinoma Antigens“ 
 
 
 
Verena Anna-Maria Stöger 
 
 
angestrebter akademischer Grad 
Magistra der Naturwissenschaften (Mag. rer. nat.)  
 
 
Wien, 2011 
 
 
Studienkennzahl lt. Studienblatt:              A 442 
Studienrichtung lt. Studienblatt:                Diplomstudium Anthropologie 
Betreuerin / Betreuer:                                Univ. Prof. Mag. Dr. Georg Krupitza 
 
 
 2 
 
1. Abstract 
This project is based on preliminary work by an interdisciplinary team of scientists. It was 
possible to identify tumor-specific proteins of lung adenocarcinoma by means of chirurgical 
gained material through proteome-analysis.  
After PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez) research, the clinical findings had been 
limited to eight useful candidates of proteins that seem to be potential tumor markers of 
cancer. The biochemical selection criteria of these proteins were membrane expression and 
extracellular secretion. Under these criteria the chance is high to find the proteins in human 
serum. There were five commercially antibodies available against the antigens of our interest.  
The aim of this diploma thesis was to test whether the antigens as specific serum markers are 
detectable in the patients’ blood samples. We tried to develop a fine-tuned ELISA for these 
proteins and to test the ELISA for its clinical suitability. 40 serum samples were collected and 
analyzed via D-ELISA and S-ELISA. Patients suffering from lung adenocarcinoma and a 
healthy control group were compared.  
This successfully established ELISA system would provide a valuable clinical tool for lung 
cancer diagnosis. It will be possible to measure the protein concentration within two days 
after blood taking from the patient. That could become a basic standard procedure for early 
diagnosis of lung tumors, in which curative resection is possible. 
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2. Zusammenfassung  
Dieses Projekt baut auf Vorarbeiten eines interdisziplinären Teams von Wissenschaftern auf. 
Aus chirurgisch gewonnenem Material wurden mittels Proteom-Analyse tumor-spezifische 
Proteine aus Lungenadenokarzinomen identifiziert.  
Nach eingehender Literaturrecherche in PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez),  
wurden nach einer ersten Auswahl acht interessante Proteinkandidaten gefunden, die 
potentielle Tumormarker zu sein scheinen.  
Die Auswahl erfolgte nach den biochemischen Kriterien der Membranständigkeit und 
Sezernierbarkeit dieser Proteine, sodaß die Wahrscheinlichkeit sehr hoch ist, diese auch im 
humanen Serum zu finden. Gegen fünf dieser Antigene gibt es kommerzielle Antikörper.  
Zielsetzung dieser Diplomarbeit war es zu testen, ob die Antigene als spezifische 
Serummarker im Blut von Patienten zu finden sind. Wir planten einen fein abgestimmten 
ELISA für jene Proteine zu entwickeln, sowie diesen ELISA für seine klinische Tauglichkeit 
zu prüfen. 40 Blutproben wurden gesammelt und mittels D-ELISA und S-ELISA analysiert. 
Patienten, die unter dem Adenokarzinom litten, wurden mit der gesunden Kontrollgruppe 
verglichen.  
Der erfolgreich etablierte ELISA könnte die Grundlage eines Standardtests zur Diagnose von 
frühen Tumoren oder die Monitorisierung von bereits diagnostizierten Lungentumoren durch 
eine einfache Blutabnahme sein. Diese Methode könnte ein Standardprozedere für frühzeitige 
Diagnose des Lungenkrebses sein, in welcher eine kurative Resektion ermöglicht wird. 
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3. Scientific Background 
3.1 Introduction 
For each patient, the diagnosis “lung cancer” is a very hard situation to cope with. This type 
of cancer represents an enormous problem in public health. The five-year survival rate has not 
turned better during the last 20 years. Fact is that during therapeutically indicated surgical 
resections of lung carcinomas, a high amount of interesting lung cancer tissue accumulates. 
This material gives the chance to identify new risk, respectively cancer markers, by using the 
incoming tissue material for recognizing novel cancer cell specifics. Via proteome-analysis, 
this lung material was used to screen for tumor-specific proteins in adenocarcinomas. Here, 
we aimed to prove whether these proteins are clinically capable in serum-test and, if yes, to 
develop a serum-test for these proteins. 
3.2 Lung cancer 
3.2.1  Lung cancer occurrence, development and classification  
Lung cancer is a common malignant disease, which is the leading cause of cancer deaths in 
the world [1]. Typically, bronchogenic cancers exist without clinical symptoms over many 
years and become clinically evident at a very late stage of the disease. This is the reason, why 
about two thirds of all cases of bronchogenic cancer are diagnosed at an incurable stage. Only 
one third of patients with this malignoma is seen by the surgeon and unfortunately just 
another third of these has got a realistic chance of getting cured. Therefore, the overall five-
year survival of patients suffering from lung cancer is as poor as 15 % [2]. The lack of 
progress in this area reflects the limited knowledge available concerning the factors that 
promote oncogenic transformation and proliferation of carcinoma cells in the lung [3]. It is a 
disappointing fact that almost no advance in this field could be achieved over the past 30 
years. Besides a few external factors, the main cause of lung cancer is surely the consumption 
of cigarettes. Almost 90% of lung cancer is caused by cigarette smoking. Although nicotine is 
one of the major ingredients of cigarette smoke and the causative agent for addiction, it is not 
a carcinogen by itself. Nonetheless, several investigators have shown that nicotine can induce 
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cell proliferation and angiogenesis. To mention the genetic analyses of Puliyappadamba et al., 
showed that the proliferative index of nicotine is different in the lung cancer cell lines H1299 
(p53-/-) and A549 (p53+/+), which indicates that the mode of up-regulation of survival 
signals by nicotine might be different in cells in the presence or absence of p53 [4]. It is now 
generally agreed that lung carcinogenesis is a multi-step process and that molecular 
alterations precede morphological, cytological and histological changes. On an epigenetic 
level, for instance it has been shown that the gene RASSF1A (3p21.3) is frequently 
inactivated by aberrant methylation in lung tumors [5]. Aberrant methylation of certain genes 
commences early during the multistage development of lung cancer. Further, the methylation 
of p16, this is already found in bronchial epithelium with mildly abnormal changes 
(hyperplasia/squamous metaplasia), has been detected [6] [7].  
 
Lung carcinomas can be divided into two major histopathologic groups:  
1.) Non-small cell lung cancers (NSCLC) 
2.) Small cell lung cancers (SCLC) 
 
Non-small cell lung cancers can be subdivided predominantly into adenocarcinomas and 
squamous cell carcinomas, and both account for 85% of lung cancer cases [8]. The rest are 
large cell carcinomas and other rare tumor types. The tumor size, lymph node status and 
possible presence of metastases determine the actual clinical stage of the disease, and is 
described in the TNM (T=primary tumor, N=regional lymph nodes, M=distant metastasis) 
staging system for lung cancer [9]. This tumor staging system is explained more detailed in 
the 6.1.1 Results section, where we list our patient cohort. 
In this study, we turned our attention to adenocarcinomas, because this type has replaced 
squamous cell carcinomas
 
as the most frequent histological subtype of lung cancer [10]. The 
WHO defines adenocarcinomas as “a malignant epithelial tumor with tubular, acinar, or 
papillary growth pattern, and/or mucus production by the tumor cell.” Fig. 1 shows a cross-
section of healthy human respiratory epithelium., showing regular cellular organization of the 
goblet cells, which are growing on a layer of basal cells that form the basal membrane by 
excreting extracellular matrix components. On the other hand, in Fig. 2 we see the disturbed 
morphology of a lung adenocarcinoma, where the goblet cells have undergone malignant 
transformation and high amounts of tumor stroma have developed. 
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Fig. 1: Visualization of respiratory epithelium of a normal lung with PAS-staining [11]  
Z:  Respiratory epithelium with cilia containing cylinder epithelial cells 
B:  Caliciform cells 
BM:  Basal membrane 
BC:  Basal cells 
 
 
3.2.2 Lung Adenocarcinoma 
The WHO-classification differentiates between papillary, solid and mucous forming 
adenocarcinomas [12]. Primary lung-adenocarcinomas are mostly peripherally localized near 
the pleura [11]. The bronchoalveolar carcinoma, or malign lung-adenomatosis, represents a 
special form of carcinoma. Lung adenocarcinomas are mostly recognized in an advanced 
stage of medical condition, because of their occurrence without symptoms over a long time.  
Fig. 2 shows the histopathological exposure of the typical adenous and papillary structure of a 
lung adenocarcinoma.  
Characteristics for this cancer type are expanded central fibrotic lesions. Problematic is the 
development of primary pulmonary adenocarcinomas to lung metastasis in many ways. 
Immunohistochemical examinations allow a distinction compared to metastases of thyroid-, 
prostate-, or hepatic carcinomas as well as other primary tumors [12]. 
The SEER population database contains information on the median survival times of patients 
with distant non–small-cell lung cancer. The database was also inspecting potential changes in 
the survival of all patients with NSCLC.   
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According to Breathnach et al. the median survival time for all patients with NSCLC in the 
SEER database showed an increase from 9.1 months in the 1973-to-1974 time period to only 
10 months in the 1993-to-1994 time period [13], indicating that an earlier detection time of 
the tumors would be essential to increase life span. 
 
 
Fig. 2: Histological section and HE-staining of lung-adenocarcinoma tissue [11]  
Picture A shows a mucous forming lung carcinoma with high amounts of tumor stroma (purple 
staining). The dark dots represent cell nuclei, which occur when abnormal cell division takes place.   
Picture B shows a tumor papilla, which is a typical feature of adenocarcinomas. The arrow represents 
a signet-ring cell. 
 
 
 
A 
B 
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3.2.3 Diagnosis and surgical treatment of lung carcinoma 
Mostly, the detection of lung cancer occurs accidentally. In the early stage, lung cancer grows 
without any symptoms. Later, when the tumor invades and touches the chest wall or upper 
parts like the plexus of the upper extremities pain can follow. Therefore, if shoulder pain is 
resistant to pain management, a simple chest X-ray is mandatory. Haemoptysis can also 
occur, when the tumor spreads out into the bronchial system. General symptoms as weight 
loss in short time period, fatigueness and actually reduction of life quality can come along 
with tumor growth.  
Primary histological verification is usually achieved by chest X-ray and CT (Computer-
Tomography), and if a lesion is detected, a bronchoscopy should be done for further 
histological analysis. Histological verification is usually achieved endoscopically in centrally 
located tumors and by CT-guided needle biopsy in peripheral lesions. Modern spiral CT 
enables a very reliable judgment concerning malignant infiltration of surrounding anatomical 
structures and enlarged mediastinal lymph node stations. In selected cases, a PET (Positron 
Emission Tomography) scan of the chest is helpful. Different therapeutical options for 
treatment are available, depending on the stage of the cancer. In early stage surgical resection 
is obligatory. If the tumor invasion exceeds the organ’s margin, a combined therapy with 
surgical resection, chemo- and radiation therapy is necessary. If surgical resection for 
anatomical reasons is not possible, a chemo- and/or radiation therapy should be done. The 
best survival rate is succeeded with surgical resection, but also conservative management can 
account for an extension of life with good quality. 
3.2.4 Clinical screening of cancer patients 
The earlier lung cancer is detected, the better are a patient’s chances to be cured. Thus, new 
methods are needed to detect lung cancer at an earlier stage when it is amenable to curative 
treatment, in contrast to its poor overall prognosis when clinical tissue alterations have 
developed. All tumor screening studies have demonstrated a significant shift towards earlier 
diagnosis and distinctly increased rates of resectability. However, no screening strategy has 
been unequivocally demonstrated to reduce lung cancer mortality [14].  
In recent years, considerable effort has led to the discovery of a number of relevant 
protooncogenes, DNA repair genes and suppressor genes which are aberrantly expressed in 
lung cancer. The pressing issue is to establish the correlation between molecular genetic 
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events and cyto-histological findings, which remain the gold standard of cancer diagnosis, and 
to identify novel biomarkers of cancer. Candidate biomarkers should have high sensitivity as 
well as specificity and appear early enough in the course of disease for medical intervention 
and to improve prognosis. Finally, the markers must be present in a biological fluid that can 
be obtained noninvasively, making its collection achievable for population-based screening 
[15]. Such molecular markers must be capable to identify individuals at the earliest stage of 
lung cancer, in which curative resection is possible. 
Nevertheless it is often quite difficult to identify proteins secreted from epithelial cells 
because the proteins in bodily fluids, such as bronchial lavage fluid and bronchial secretions 
or in cancer tissue specimens include also a lot of proteins derived from circulating blood and 
mixed cell types, as well as stromal and inflammatory cells [16]. 
3.2.5 The interest in bio-markers    
According to Hanash et al., the expected outcome of the development of panels of biomarkers, 
allows firstly early detection of cancer and secondly prediction of the probable response to 
therapy. The general goal of the cancer biomarker field is to develop simple non-invasive 
tests. These tests indicate cancer risk, allow early cancer detection and classify tumors. This 
basic approach is useful for the patient to receive the most appropriate therapy and monitor 
disease progression, regression and recurrence [17].  
By detecting cancer at an early stage, it would become possible to harness the immune 
response directed against tumor antigens. It has been demonstrated that a number of 
intracellular and cell-surface antigens are detectable in sera from patients with different 
cancer types. The identification of a panel of antigenic biomarkers that are tumor-specific 
could be an effective strategy for cancer screening.  
The immune response for identifying cancer biomarkers is remarkable, because the immune 
system carries out a biological amplification (= antibodies) that generates a detectable 
response to antigenic tumor proteins. Many strategies have been pursued for determining the 
repertoire of antibodies in the sera of patients with cancer. The most relied-on approach for 
validation remains the sandwich enzyme-linked immunosorbent assay (S-ELISA), which 
is also the outcome for the experiments of this diploma thesis.  
Because of its highly specificity of using a pair of antibodies against the targeted molecule, it 
seems to be a very attractive strategy. Anyway, the use of antibodies directed against a serum 
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containing lung tumor proteins of interest would have utility for elucidating those proteins 
with the greatest diagnostic advantage [18]. 
In compliance with Hanash et al. it is quite unrealistic to expect that a single biomarker will 
reflect all information about tissue type and malignant transformation throughout the various 
stages of tumor development and progression. After all, reliable panels of biomarkers are 
urgently needed, whose identification will be true a challenge [17].  
3.3 Proteomic characterization of lung cancer tissue 
It was attempted to identify tissue-specific differences between healthy and lung tumor tissue. 
The collaborating pathologists transferred fresh surgically removed tumor and lung tissues 
from the clinics to a biochemist laboratory, where proteome analysis achievement was 
performed. More specifically, protein samples from 5 tumors and 5 control tissues were 
digested, protein was extracted and subjected to 2D gel analysis and a comparative spot 
analysis was performed. Candidate protein markers for tumor specificity (i.e. differently 
expressed proteins) were identified by mass spectroscopy and compared with a tissue 
proteome databank available at the biochemists´ laboratory. Additionally, the worldwide 
“Swiss-Prot” database (http://expasy.org/) was screened with the protein candidates. This 
work package reveals functions of protein markers and contributed valuable information 
about their plausibility as specific tumor antigens. The criteria for picking potential tumor 
marker candidates were (1) lung tissue specificity and/or (2) tumor specificity. 
3.4 Tumor Antigens 
The analysis of five tumors and corresponding controls, as well as the comparison with 
proteome databanks revealed the following eight proteins with the according information as 
promising candidates for serum analysis:   
 
 Cytoglobin (CYGB) (Stellate cell activation-associated protein) - Homo sapiens (Human), 
expressed in endothelial, stellate, melanoma cells and fibroblasts, known to be 
overexpressed in tumors; may have a protective function during conditions of oxidative 
stress, may be involved in intracellular oxygen storage or transfer.  
 Gametogenetin (GGN) - Homo sapiens (Human), few information. 
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 Progastricsin (PGC) - Homo sapiens (Human), secreted enzyme. 
 Interleukin-18 precursor (IL-18) (Interferon-gamma-inducing factor) (IFN-gamma-
inducing factor) (Interleukin-1 gamma) (IL-1 gamma) (Iboctadekin) - Homo sapiens 
(Human); not tumorspecific, however a promising marker for inflammatory reaction.  
 Mesothelin precursor (MSLN) (Pre-pro-megakaryocyte potentiating factor) (CAK1 
antigen) [Contains: Megakaryocyte-potentiating factor (MPF); Mesothelin, cleaved form] 
- Homo sapiens (Human), known to be quite tumor specific.  
 Mucin-5B precursor (MUC5B) (Mucin-5 subtype B, tracheobronchial) (High molecular 
weight salivary mucin MG1) (Sublingual gland mucin) - Homo sapiens (Human), 
typically not tumor-specific, but unexpected in lung tissue.  
 Neudesin precursor (NENF) (Neuron-derived neurotrophic factor) (Secreted protein of 
unknown function) (SPUF protein) - Homo sapiens (Human). 
 Proapoptotic caspase adapter protein (PACAP), Homo sapiens. 
After the definition of tissue-specific differences, it was the aim to explore whether or not 
these eight candidate proteins were (1) assessable and (2) quantifiable in the sera of lung 
tumor patients.  
Therefore, the availability of antibodies against the suggested potential tumor markers was 
examined by an internet search via the “biocompare” platform 
(http://www.biocompare.com/), a product directory linked with a search engine. The retrieved 
list of antibodies commercially available was checked regarding antibody specificity, 
performance in ELISA, and pricing. Concerning antigens lacking availability of commercial 
antibodies, academia will be searched through via the “PubMed” publication browser 
(http://www.ncbi.nlm.nih.gov/sites/entrez). We identified five commercially antibodies. To 
start the development and evaluation of serum tests, we decided to work with the four bold 
marked proteins:   
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Pos: Protein Antibodies from Producer 
1 Cytoglobin Antibodies by Santa Cruz 
2 Gametogenetin no commercially available antibody found 
3 Gastricsin no commercially available antibody found 
4 Interleukin 18 Antibodies by Acris, Gene Tex, GenWay 
5 Mesothelin Antibodies by Abbiotec, LifeSpan, Novus, Rockland 
6 Mucin 5B Antibodies by LifeSpan, Millipore 
7 Neudesin no commercially available antibody found 
8 PACAP Antibodies by Abbiotec, Abcam, Acris, Invitrogen, 
Proteintech, Novus Biologicals 
 
Table 1: Table showing commercially available antibodies against tumor antigens 
The bold marked proteins in the table represent the tumor markers, which were aimed to be tested in 
the ELISA experiments.  
 
In the following chapters, the four tumor antigens, which were the basis of the immunological 
experiments of this thesis, are shortly presented. The tables for each antigen show the accurate 
commercially acquired antibodies for the antigens and can be seen in Materials and Methods. 
 
3.4.1 Cytoglobin (CYGB) 
CYGB is part of the globins, which are a family of heme-containing proteins, which 
reversibly bind oxygen. They have been described in animals, plants, protists, fungi and 
bacteria [19] [20].  
The following four mammalian globins have been identified already [21] [22] [23] [19]:  
- Hemoglobin  
- Myoglobin  
- Neuroglobin  
- Cytoglobin  
 
CYGB is a recently discovered vertebrate globin and is distantly related to myoglobin. 
Unfortunately, Neuroglobin and Cytoglobin have functions that are not completely 
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understood [21] [23].  CYGB is assigned to the chromosomal region 17q25, that is frequently 
lost in multiple malignancies.  
There exist recent studies, which provide preliminary evidence for increased methylation of 
the gene in lung cancer. Shivapurkar et al. investigated the role of CYGB as a tumor 
suppressor gene. They detected the tumor specificity of CYGB methylation in patients with 
and without lung cancer. Furthermore, they could show in their assays the tumor specificity of 
CYGB gene methylation [24]  in multiple other epithelial and hematologic malignancies.  
 
3.4.2 Interleukin 18 (IL-18) 
IL-18 is known as a pro-inflammatory cytokine, essential for the host defense against 
intracellular infection [25]. It is produced by activated macrophages and dendritic cells, 
showing  potent interferon IFN-γ inducing activity [26] [27] [28]. It’s biological role is the 
increase of the activity of cytotoxic T-lymphocytes and natural killer cells [26] [29]. 
IL-18 also  induces gene expression and synthesis of TNF, IL-1 and a number of  chemokines 
[25]. Shi et al. demonstrated that IL-18 promotes autoreactive Th1-cell development in part 
via induction of IFN-γ by NK cells [27]. IL-18 shows similarities with proteins of the IL-1 
family [25] in structure and function and shares some biological activities with IL-12 [27] 
[30]. Comparing IL-18 and IL-1beta, they share significant primary amino acid sequences and 
are related folded as all-beta sheet molecules. At first, IL-18 is synthesized as a biologically 
inactive precursor molecule with a lacking signal peptide. As a result of studies, the IL-18 
precursor requires cleavage into an active, mature molecule by the intracellular cysteine 
protease. This cystein protease is called IL-1beta-converting enzyme (ICE), which is also 
known as caspase 1 [25].  
Farjadfar et al. explored in their study the association between IL-18 polymorphism and lung 
cancer. They suggested that IL-18 polymorphism contributes to lung cancer risk, particularly 
among patients suffering from squamous cell carcinoma. Farjadfar described significant 
differences in the IL-18-607 allele and genotype distributions between 73 lung cancer patients 
and controls. Further studies with larger numbers of patients are necessary to determine the 
possible association between IL-18 polymorphisms and different histological types of lung 
cancer [31]. 
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3.4.3 Mesothelin (MSLN) 
Mesothelin seems to be a promising predictive marker for early evidence of malignant 
mesothelioma, as several authors have proposed already [32] [33] [34] [35] [36]. 
MSLN, which is a differentiation antigen that was first described as the antigenic target of the 
monoclonal antibody K1 [37], is a cell surface protein present on normal mesothelial cells 
lining the body cavities, including the pleura, peritoneum, and pericardium [38]. It is highly 
expressed in many cancers, including mesotheliomas, ovarian and pancreatic cancers, and 
some squamous cell carcinomas [39] [40]. Cristaudo et al. stated that the human mesothelin 
gene codes for several proteins and is consistently expressed in normal mesothelial cells. 71-
kDa precursor protein is the primary product of the gene which undergoes physiologic 
cleavage, which is resulting in two main proteins. One is the 31-kDa NH2-terminal 
megakaryocyte potentiation factor, which is normally secreted into the blood [32]. The 
COOH-terminal product of the cleavage is anchored to the cell membrane and supplies 
epitopes detected in immunohistochemistry. After further proximate cleavages, this cell 
surface protein releases soluble mesothelin-related peptides (SMRP). These peptides are the 
principal mesothelin family proteins [32] [33] [34]. Hassan et al. mentioned that cell-bound 
MSLN is a promising target for antibody based treatment of cancers overexpressing MSLN. It 
is also an immunogenic protein and anti-MSLN antibodies are frequently detected in patients 
with mesotheliomas as well as ovarian cancer [39] [41].  
3.4.4 Mucin 5B (MUC5B) 
Mucins are complex glycoproteins the major macromolecular constituents of the bronchial 
mucous layer conferring its viscoelastic characteristics by covering the airway epithelia. They 
have a leading to high carbohydrate content (50–90% by weight) due to heavy protein 
glycosylation, high molecular weight (2–20*105 Da), and therefore they are difficult to isolate 
and purify [42] [43]. Mucins play an essential role in protecting and lubricating the epithelial 
surface of various tissues [44]. The tandem repeats (TR) characterize a mucin protein. Mucins 
differ in the amount of these domains, especially from membrane-bound receptors. 
Furthermore, mucins are classified by their MUC protein backbone, disposing of 377 to  
≥ 11.000 amino acids in their protein backbones. The backbone is encoded by the MUC gene 
[43].  
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MUC5B is one of the major airway mucins and has got TR domains that are repeated four or 
five times in their protein backbones. They are separated by cysteine-rich domains (Fig. 3). 
 
 
 
Fig. 3: Schematic drawing of a MUC5B protein backbone [43]. (Models adapted primarily 
from Dekker et al.) 
The region marked with n shows the number of TR of MUC5B. The pink colored ends represent the 
C-terminal domain.  
 
Historically, Mucins have been implicated since long in health and disease, especially in the 
fields of cancer, lung diseases [45], gastrointestinal diseases, as well as concerning mucins 
expressed in the eye and ear. Mucus and mucins are overproduced in the airways of patients 
with chronic airway diseases like COPD or CF. The characteristics of these diseases are 
inflammatory and immune response mediators, which are released into airway tissue and 
airway secretions. It is now possible to identify specific mucins in airway samples, because 
MUC-specific antibodies are available [43]. 
 
3.5 Antibodies against Antigens 
Antibodies are glycoproteins, also named immunoglobulins (Ig). They are secreted into blood 
and extracellular liquids or are fixed on the surface of B-lymphocytes. 
The most common antibodies in human serum are the so called IgGs (Immunoglobulin G) 
[46]. Antibodies bind their accurate antigen and recruit other cells and molecules of the 
immune system, which finally eliminate the antigen of the organism [47]. The molecular 
structure is “Y”-shaped. The compound elements of all polypeptide chains are basically 
covalent disulphide bridges. When immunoglobulins get disassembled, four subunits can be 
detected, of which two are always identical [48]: 
- Two heavy chains (H-chains) 
- Two light chains (L-chains) 
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Fig. 4: Graphical representation of an immunoglobulin molecule [12] 
The picture above shows the typical antibody structure with the H-chain and L-chain, which are 
binding with disulphide bridges. Both chains are labeled through variable and constant regions. The 
variable regions defined the antigen binding place. The so called hinge-region is located between the 
Fc and Fab regions that confer mobility on the two Fab arms of the antibody molecule, which allows 
it to combine better with the two epitopes.  
 
There are only two types of L-chains which are either of lambda or kappa type, but there exist 
five main classes (IgM, IgG, IgD, IgE, IgA) of the H-chains.  
Leucocytes play an important role in the specific and unspecific immune defense. Especially 
two subtypes, B cells and T cells, are essential for the formation of antibody-antigen complex. 
B cells and T cells generate an antigen receptor and express it on the surface to finally bind 
the antigen [49]. The paratope, or antigen binding place of the antibody, connects reversible 
to the fitting structure of the antigen [47]. The part of the antigen which binds to the paratope, 
is called epitope. Although antibodies are highly selective, they nevertheless show cross 
reactivity to similar epitopes of other antigens [47]. 
The general production of antibodies is done by immunizing animals, like rabbits, goats, 
mice, etc. and afterwards the extraction of the immunized animal’s sera. Polyclonal 
Antibodies are a mixture of different antibodies which can recognize a specific epitope or 
different epitopes (f. ex.: an antigen with multiple epitopes).  
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Monoclonal Antibodies result through fusion of antibody-producing B-cells, from the spleen 
of an immunized mouse, with cells from hybridoma cell lines. 
 
In this study we discuss especially the four antibodies anti-Cytoglobin, anti-Interleukin 18,           
anti-Mesothelin and anti-Mucin 5B, which have been generated in mice and/or rabbits 
against the four correspondent tumor antigens in our lung adenocarcinoma patients. 
 
3.6 The ELISA   
ELISA stands for “Enzyme Linked Immuno-Sorbent Assay”. The ELISA-system is one of 
the most prominent used methods in immunochemistry and it is applied in fields like clinical 
diagnostics, veterinary diagnostics, pharmaceutical diagnostics, as well as food- and 
environmental analysis.  
The basic of this technique is the unique specificity of the antibody-antigen-binding, the 
recognition of a specific antigen surface structure, the epitope. The reactant (antibody or 
antigen) is bound on a fixed phase (f. ex.: microtiter plate) and interacts with the antigen or 
antibody. The formation of the immune complex is then detected by an enzymatic color 
reaction. Normally, the antibody (mostly Secondary Antibody) is covalently linked to an 
enzyme. The color intensity is measured with a spectrometer. Finally, the optical density  
(= OD-value) of the colored solution can be directly correlated with the concentration of the 
coated (= Direct ELISA) or captured (= Sandwich ELISA) antigen. In order to control 
pipetting and handling errors, at least double values of the same sample concentrations are 
performed and the mean OD-values and standard deviations are calculated. 
The following picture (Fig. 5) shows the principle of the color reaction of an ELISA. 
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Fig. 5: Enzymatic color reaction of an ELISA 
The enzyme catalyzes the reaction and changes a colorless substrate into a dyed one. The more 
immune complexes are present, the higher is the so-called optical density OD-value. This effect makes 
the amount of antigen-antibody- reaction measureable. (adapted from http://virology-microbiology-
b.blogspot.com/) 
 
Fig. 6: Typical format and outcome of an ELISA experiment  
(adapted from http://www.med4you.at/laborbefunde/lbef_anca.htm) 
 
The ELISA establishment itself and certain application/conditions is a procedure that differs 
from lab to lab, because of the high variety of the interactions. Many factors influence the 
outcome of an ELISA experiment. These include the choice of the correct antibody- and 
antigen- dilutions, the reagents, incubation times, the coated amount of antibody and/or 
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antigen, as well as the choice of enzymatic color reaction and subsequent measurement of 
photometry data. Important is the selection of the correct microtiter plate. In this study I 
worked with Nunc MaxiSorp® 96 well plates, because of their surface quality to bind all 
types of molecules (Fig. 7). 
 
Fig. 7: Schematic drawing of a MaxiSorp® well plate [47] 
The picture shows that all macromolecular types can bind on the surface modification.  
MaxiSorp® is a polystyrol surface with a high bond capacity for proteins and other molecules with 
hydrophobic and hydrophilic areas. This allows the immobilization of antibodies. PolySorp®, 
MultiSorp® and MediSorp® have got different characteristics to accomplish experimental designs.  
 
My experiments were accomplished with two main test formats: 
- Sandwich-ELISA (S-ELISA) 
- Direct-ELISA (D-ELISA) 
 
The principle of the Sandwich ELISA system is to measure the amount of antigen brought 
between two layers of antibodies ( Capture- and Detection Antibody). The importance is 
that the antigen to be measured must contain at least two antigenic sites capable of binding to 
antibodies. It is possible to use either Monoclonal or Polyclonal Antibodies acting as Capture- 
and Detection Antibodies in Sandwich ELISA systems. The difference between the two 
antibody types is that Monoclonal Antibodies recognize a single epitope which allows fine 
detection and quantification of small differences of the antigen amounts, whereas Polyclonal 
Antibodies are often used as the Capture Antibody to pull down as much of the antigen as 
possible on the plastic surface. The advantage of Sandwich ELISA is that it is up to 2 to 5 
times more sensitive than direct ELISAs. S-ELISAs are preferred when targeting bigger 
antigen-structures like antibodies, viruses, proteins, etc.  
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The advantage of D-ELISAs is the strong signal-amplification, because of the ability of 
enzyme-linked Secondary Antibodies (Tracer-Antibodies), to bind tracers per Primary 
Antibody [47]. The graphics below (Fig. 8) shows the principle of work flow of an S-ELISA 
versus a D-ELISA: 
 
 
 
 
      
Fig. 8: Schematic comparison of an S-ELISA and an D-ELISA [47] 
A: S-ELISA: The well is coated with a Capture Antibody, before the antigen (analyte) is added. The 
antigen will bind to the Capture Antibody. A Detecting Antibody (Secondary-Antibody) is added and 
binds to the antigen. After adding the POX- (peroxidase) antibody, the ELISA-reader evaluates the 
absorbency of the plate wells to determine the presence and quantity of the antigens. 
B: D-ELISA: The D-ELISA is the same procedure just without using a Capture Antibody.  
The POX-antibody will bind again to the Secondary Antibody. 
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4. Aim of the Thesis 
Due to preliminary work by an interdisciplinary team of scientists, it was possible to identify 
tumor-specific proteins of lung adenocarcinoma by means of chirurgical gained material 
through proteome-analysis. After PubMed research, the clinical findings had been limited to 
eight useful candidates of proteins that seem to be potential biomarkers of cancer. The 
biochemical selection for these, were membrane expression and secretion criteria of these 
proteins. Under these criteria the chance is high to find the proteins in human serum, because 
they should have high sensitivity and specificity to belong to lung cancer, especially when 
they appear early enough in the course of disease for medical intervention to improve 
prognosis. 
There were five commercially available antibodies against the antigens of our interest. The 
aim of this diploma thesis was to test, whether the antigens as specific serum markers are 
detectable in the patients’ blood samples. 
The aim of my thesis was to develop a fine-tuned ELISA for these proteins and to test the 
ELISA for its clinical suitability. 40 serum samples were collected and analyzed via D-ELISA 
and S-ELISA. Patients carrying tumor markers and a healthy control group were compared. 
This successfully established ELISA system would provide a valuable clinical tool for lung 
cancer diagnosis. Provided that the methodology (antibody quality) can be successfully 
established, it will be possible to measure the protein concentration within two days after 
blood taking from the patient. That could become a basic standard procedure for early 
diagnosis of lung tumors, in which curative resection is possible. 
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5.  Material and Methods  
5.1 Reagents – Buffers and Solutions 
10 x PBS (1 liter) 
5.244 g NaH2PO4 * H2O 
28.83 g Na2HPO4 * 2H2O 
Distilled water was added to a volume of 1000 ml and pH was adjusted to 7.4 
 
1 x PBS (1 liter) 
100 ml 10 x PBS 
Distilled water was added to a volume of 1000 ml 
 
0.2 % PBST (1 liter) 
100 ml 10 x PBS 
2 ml Tween 20 
Distilled water was added to a volume of 1000 ml 
 
Carbonate Buffer (1 liter) 
1.59 g Na2CO3 
2.93 g NaHCO3 
0.20 g NaN3 
Distilled water was added to a volume of 1000 ml and pH was adjusted to 9.0-9.6 
 
Wash Buffer (1 liter) 
1000 ml 1 x PBS 
0.5 ml Tween 20 
 
10 x TBS (1 liter) 
24.5 g Tris 
80.0 g NaCl 
Distilled water was added to a volume of 1000 ml and pH was adjusted to 7.6 
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Blocking Buffer (0.5 liter) 
5 g (1%) BSA 
0.5 ml Tween 20 
Adjust 1 x PBS to 500 ml 
 
Assay Buffer (1 liter) 
5 g (0.5%) BSA 
0.5 ml Tween 20 
Adjust 1 x PBS to 1000 ml 
 
TMB - Substrate Solution  
Add 50 µl to each well to let start color reaction 
 
TMB- Stop Solution 
Add 50 µl to each well to stop the color reaction 
 
ELISA “Color Buffer” (1 liter) 
5.1 g C6 H8 O7 *H2O 
9.15 g Na2 HPO4 * 2H2O 
Distilled water was added to a volume of 1000 ml 
 
ELISA Reaction Buffer with Phenylenediamine (for 1 plate) 
6 mg Phenylenediamine  
15 ml “color buffer” 
Add 6 µl (30%) H2O2  just before pipetting to the wells 
Add 100 µl to each well 
 
Stop Solution for Reaction Buffer 
Add 50 µl 8N H2 SO4  quickly to each well 
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Additional components of IL-18 Kit from Bender MedSystems® without exact descriptions 
of the content are: 
 
Standard Protein (S): BMS267/2MSTS (for 10 assays) 
Coating Antibody (CA): BMS267/2MSTCA 
Sample Diluent (SD): BMS267/2MSTSD 
Biotin-Conjugate (BK): BMS267/2MSTBK 
Streptavidin-HRP (PK): BMS267/2MSTPK 
 
ELISA plate reader: Synergy HT BIO-TEC® 
OD-values were evaluated and visualized with Microsoft Excel software. 
 
 
5.2 Methods 
5.2.1 Establishment of ELISAs using recombinant Antigens 
Before we started to use the collected serum samples, we aimed to establish a suitable 
antigen-specific ELISA. The appropriate antigens and antibodies were subjected to 
preliminary checkerboard titrations in order to determine the optimum concentration ranges of 
antigen and sera as well as antibodies used in the assay.  
 
The general test procedure for the establishment of the S-ELISA was as follows:  
 
1) The appropriate Capture Antibody (Primary Antibody) was diluted in 1 x PBS. In 
order to establish ideal conditions, the dilutions differed between each experiment. 
However, always 100 µl of the coating solution was added to each well. Immediately 
after coating and before coating overnight, the microtiter plates were sealed with an 
adhesive film. The plate was stored overnight at 2°C, allowing antigen/antibody 
binding process to take place.  
2) On the following day, the plate was washed once with 400 µl Wash Buffer. After the 
washing step, the plate was tapped on absorbent pad or paper towel to remove excess 
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Wash Buffer.  250 µl of Blocking Buffer were added to each well and incubated at 
room temperature for 2 hours. Washing steps were repeated two times.  
3) The antigen, in our case the recombinant proteins (CYGB / IL-18 / MSLN / MUC5B), 
was diluted in Assay Buffer to start a geometric dilution series. The starting dilution 
differed from each experiment but always contained two blank wells for the negative 
control. The serum samples were commonly diluted in Sample Diluent, mostly 1:2, 
but dependent on the pretests. 100 µl of the diluted antigen- or serum sample mixture 
was coated per well on a 96- well plate (Nunc MaxiSorp®) overnight at 2°C. Serial 
dilutions were always dispensed in duplicates.  
4) On the next day, the plates were washed 4 times. Plates were blocked again with 250 
µl Blocking Buffer for 2 hours at room temperature. 
5) The Detection Antibody (Secondary Antibody) was diluted in Assay Buffer and 
dilutions differed between each experiment. Mostly we used a dilution factor of 1:500.  
50 µl of this dilution was added to the wells. Plates were incubated for 1 hour at room 
temperature. Washing steps were repeated 6 times (see above).  
6) The dilution of POX- labeled antibody was prepared in Assay Buffer and the common 
dilution factor was 1:4000. 100 µl were added per well and incubated for 1 hour at 
room temperature. Then 6 washing steps were done. 50 µl TMB-Substrate Solution 
were added to all wells. The microwells were incubated at room temperature for 
approximately 10 minutes with avoiding direct exposure to intense light.  
7) 50 µl of the TMB-Stop Solution were quickly and uniformly spread to stop the 
enzyme reaction. The ELISA plate reader monitored the results by reading the 
absorbance of each microwell using 450 nm as wave length. The OD-value was used 
to define the results and produce statistical analyses via Excel tables and t-tests. OD-
values measured in the linear range between 0.3 and 1.2 were suitable for valid 
antigen detection. 
 
 
For Direct ELISAs (D-ELISA), the protocol was the same as for Sandwich ELISAs, but 
without using Capture Antibodies for coating. 
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5.2.2 Human blood samples and serum preparation 
Fresh serum samples were collected by the clinical cooperator, documented and transferred to 
our laboratory. The advantage of this method is that blood can be easily and routinely taken 
from the patients. All patients had not received any pharmacological treatment prior to our 
analyses. The serum samples are still available for further studies analyzing additional 
proposed tumor marker candidates. 
Approximately 5-10 ml human venous blood was taken for our analysis. All blood samples 
were resinated 1:10 with the protease-inhibitor trasylol and rapidly cooled. Trasylol, also 
called aprotinin, is the bovine version of the small protein basic pancreatic trypsin inhibitor. 
This enzyme inhibits trypsin and related proteolytic enzymes. Trasylol’s main effect is to 
slow down the fibrinolysis, which is the process that leads to the breakdown of blood clots 
[50]. For serum exploitation, the blood samples were coagulated under air and centrifuged for 
10 min/3000 rpm. The serum supernatant was collected and stored in tubes at 3°C, where they 
can be used over a period of several months.  
 
 
Fig. 9: Preparation of the collected serum samples 
After the spin down of the blood, the serum samples were filled in tubes and marked with ascending 
numbers to differ between lung adenocarcinoma-patients and healthy control group. These tubes were 
stored in the cold room at 3°C.  
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5.2.3 Cytoglobin ELISA 
The following table shows the commercially available recombinant protein and the two 
antibodies that were used to establish a Direct ELISA or Sandwich ELISA:  
 
Recombinant Protein    
(Abnova)                     
CYGB 
Anti-CYGB (Santa Cruz)   
Rabbit polyclonal antibody 
Anti-CYGB (Abnova)      
Mouse monoclonal antibody 
Catalog ID         
H00114757-P01 
Catalog ID                         
sc-66855 
Catalog ID         
H00114757-M02 
Concentration                
0.08 µg/µl 
Concentration                 
200 µg/ml 
Concentration                     
1 mg/ml 
Amino acid sequence          
1 a.a.-191 a.a.                    
full-lenght with GST-tag 
Amino acid sequence     
raised against                
amino acids 1-190 
Amino acid sequence          
1 a.a.-191 a.a.                    
full-lenght with GST-tag 
 
Table 2: Summary of commercially available Cytoglobin recombinant protein and antibodies 
 
Reagents: 
 Recombinant protein CYGB (Abnova; H00114757-P01) 
 Anti-CYGB rabbit antibody (Santa Cruz; sc-66855) 
 Anti-CYGB mouse antibody (Abnova; H00114757-M02) 
 POX- anti- mouse antibody 
 POX- anti- rabbit antibody 
 Sera dilutions 
 Assay Buffer 
 Blocking Buffer 
 Carbonate Buffer 
 1x PBS 
 0.2% PBST 
 Wash Buffer 
 ELISA Reaction Buffer with Phenylenediamine 
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 8N H2 SO4   
 TMB-Substrate Solution 
 TMB-Stop Solution 
 
The following protocol describes the general procedure for CYGB-ELISA tests. It contains 
descriptions for the establishment of Direct ELISA and Sandwich ELISA, as well as operating 
the sera. The protocol is the same, but sometimes the reagents and dilution series differed by 
actual need.  
 
1) After delivery of the recombinant CYGB, it was immediately stored in aliquots at -
80°C, to avoid repeated thawing of the antigen, which could lead to degradation. To 
establish the optimum standard curve, we diluted the stock-solution of CYGB. The 
dilution range of the protein was between 250 ng/ml and 0.15 ng/ml. The CYGB 
protein was mixed mostly in Carbonate Buffer or 1x PBS before we prepared the 
geometric dilution series. 100 µl were added to each well according to plan. 
Additionally, of wells one row was only filled with 1x PBS or Assay Buffer, as a 
negative control.  
2) When we established the S-ELISA system, we commonly diluted the Capture 
Antibody (Primary Antibody) 1:250 in 1x PBS or Assay Buffer. 100 µl were added 
into each well according to plan. Immediately after pipetting, the microtiter plates 
were sealed with an adhesive film. The plates were stored overnight at 2°C, allowing 
the binding process to take place.  
3) On the following day, the plates were washed once with 400 µl Wash Buffer. After the 
washing step, the plates were tapped on absorbent pad or paper towel to remove 
excess Wash Buffer. 250 µl of Blocking Buffer were added to each well and incubated 
at room temperature for 1 hour. Washing steps were repeated two times.  
4) When we included the serum samples, we used a dilution range between 1:2 - 1:2000. 
The sera were diluted in Sample Diluent. 100 µl of the diluted serum sample mixture 
was coated per well and stored overnight at 2°C. On the next day, the plates were 
washed 4 times. Plates were blocked again with 250 µl Blocking Buffer for 1 hour at 
room temperature. 
5) The Detection Antibody (Secondary Antibody) was diluted in Assay Buffer or 1x PBS 
and dilutions differed between each experiment. Dilutions ranged between 1:500 and 
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1:32000. 50 µl were added per well for 1 hour at room temperature. Washing steps 
were repeated 6 times.  
6) POX-anti-rabbit or POX-anti-mouse antibody was commonly prepared in Assay 
Buffer and the dilution factor was always 1:4000. 100 µl were added per well and 
incubated for 1 hour at room temperature. Then 6 washing steps were done. We used 
two different methods for visualizing the enzyme reaction: 
 
a) An ELISA Reaction Buffer with Phenylenediamine (see description in Materials 
Reagents - Buffers and Solutions) was prepared. 100 µl of this mixture was added to 
each well and incubated at room temperature for approximately 10 minutes. After that 
time, the color reaction was stopped by adding 50 µl 8N H2SO4. The color intensity 
can be read by the ELISA plate reader at 490 nm and 630 nm. 
b) As an alternatively method, we also used TMB Substrate. Afterwards 6 repeats of 
washing steps, 50 µl of TMB-Substrate Solution was quickly added to all wells and 
incubated at room temperature for about 10 minutes. We avoided the direct exposure 
of the plate to intense light. The enzyme reaction was stopped by adding 50 µl TMB-
Stop Solution to all wells. The absorbance can be read at 450 nm. 
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5.2.4 CYGB Dot Blot  
We aimed to test whether the two commercially available antibodies react appropriately with 
the antigen. Therefore, a Dot Blot was performed.  
   
Reagents: 
 Anti- CYGB antibodies  
(Santa Cruz rabbit sc 66855 and Abnova mouse H00114757-M02) 
 CYGB- recombinant protein (Abnova H00114757-P01) 
 POX-anti-rabbit and POX-anti-mouse antibody 
 TBST 
 Whatman® Protan® Nitrocellulose Transfer Membrane 
 5% Nonfat dry milk  
 5% BSA 
 
1) The CYGB antigen stock-solution was 80 ng/µl. The 1:8 dilution was achieved by 
mixing 2µl of the antigen in 14 µl PBS. A geometric dilution series of recombinant 
CYGB protein started at 20 ng and ended at 1.25 ng by dropping the dilutions on the 
Nitrocellulose Membrane.  
2) The membrane was dried on air for a few minutes. Afterwards the membrane was 
blocked with 5% nonfat dry milk in TBST on a microplate shaker for 1 hour at room 
temperature. Then it was washed 2 times in TBST.  
3) Dilutions of the Primary Antibodies were prepared in TBST/5% BSA and were added 
for 1 hour at room temperature. Anti- CYGB antibody (Abnova) was diluted 1:500 
and Anti- CYGB antibody (Santa Cruz) was diluted 1:200.  
4) Next, the membrane was washed 3 times for 5 minutes in TBST. The Secondary 
Antibodies (POX-anti-rabbit and POX-anti-mouse antibody) were diluted 1:3500 in 
5% nonfat dry milk in TBST, added to the membranes and left on the microplate 
shaker for 1 hour at room temperature. The membrane was washed 3 times for 15 
minutes in TBST. 
5) The chemoluminescence reaction with ECL Plus reagent (GE Healthcare Amersham) 
was detected in the LUMI Imager (Boehringer Ingelheim).  
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5.2.5 CYGB Western Blot 
Reagents: 
 Recombinant protein CYGB (Abnova; H00114757-P01) 
 Anti-CYGB rabbit antibody (Santa Cruz; sc-66855) 
 POX-anti-rabbit antibody 
 Serum samples P1-P13 
 LSB + 
 5% milk powder 
 TBST 
 ECL-Plus 
 
1) 1 µl, 2 µl and 3 µl of the recombinant CYGB protein were mixed with LSB +. This 
mixture was pipetted in each case to 13 tubes. Afterwards 3 µl serum (P1-P13) was 
added into the appropriately numbered tubes. 
2) Furthermore, samples were incubated for 10 minutes at 95°C to denature the proteins 
and then centrifuged for approximately 2 minutes.  
3) 20 µl were loaded on the polyacrylamid gel (10% PAGE) into every slot. The gel ran 
at 120 V for about 1 ½ hours. The proteins were transferred on nitrocellulose at 23 V 
overnight.  
4) The blots were blocked with 5% milk powder in TBST and then washed 3 times with 
TBST. The Primary anti-CYGB Antibody was diluted 1:200 in 5% BSA in TBST and 
added to the blots and incubated for1 hour at room temperature. After that, 3 washing 
steps with TBST followed for 5 minutes each.  
5) The POX-labeled Secondary Antibody was diluted 1:3000 in 5% milk powder in 
TBST, added to the blots and shook for 1 hour at room temperature. 3 washing steps 
with TBST followed.  
6) The photoreaction with ECL Plus Westernblotting Detection System (GE Healthcare 
Amersham) was detected in the LUMI Imager (Boehringer Ingelheim).  
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5.2.6 Interleukin 18 ELISA 
The following table shows the commercially available recombinant protein and the two 
antibodies that were used to achieve a Direct ELISA or Sandwich ELISA: 
 
Recombinant Protein   
(Everest Biotech)                                      
IL-18 
α-IL-18 (Everest Biotech)    
Goat polyclonal antibody  
IL-18 Module Set      
(Bender MedSystems®)      
see Table 4                                 
Catalog ID                      
EBP09393                           
Catalog ID                         
EB09393 
 
Concentration                         
100 µg of dried peptide 
Concentration                          
0.5 µg/µl 
 
Amino acid sequence               
C-NPPDNIKDTKSDI 
Amino acid sequence               
C-NPPDNIKDTKSDI 
 
 
Table 3: Summary of commercially available Interleukin 18 protein and antibodies 
 
The following table (Table 4) shows information about the reagents of the Module Set from 
Bender MedSystems® (BMS267/2MST) for the development of the Sandwich ELISA with 
anti-Human IL-18 Matched Antibody Pairs. This purchased S-ELISA was done with IL-18, 
because no 2
nd
 antibody from a different species was commercially available.  
 
Standard Protein       
IL-18 
Coating Antibody            
anti-human IL-18 
monoclonal antibody 
Biotin-Conjugate        
anti-human IL-18 
monoclonal antibody 
Streptavidin-HRP 
Concentration          
100 ng/ml            
lyophilized protein 
Concentration          
Vial (1.1 ml)         
100 µg/ml  
Concentration          
Vial 55 µl 
Concentration            
22 µl 
 
Table 4: Summary of reagents from Bender MedSystems® Module Set for human IL-18 
 
 
 
 38 
 
Reagents: 
 Recombinant protein IL-18 (Everest Biotech; EBP09393)   
 Anti-IL-18 goat antibody (Everest Biotech; EB09393) 
 Standard protein IL-18 (Module Set) 
 Coating antibody (Module Set) 
 POX- anti- goat antibody 
 Biotin-Conjugate (Module Set) 
 Streptavidin-HRP (Module Set) 
 Sera dilutions 
 Assay Buffer 
 Blocking Buffer 
 Carbonate Buffer 
 1x PBS 
 0.2% PBST 
 Wash Buffer 
 ELISA Reaction Buffer with Phenylenediamine 
 8N H2 SO4   
 TMB-Substrate Solution 
 TMB-Stop Solution 
 
The following protocol describes the general procedure for IL-18-ELISA tests. It contains 
descriptions for the establishment of Direct ELISA and Sandwich ELISA, as well as operating 
the sera. The protocol is the same, but sometimes the reagents and dilution series differed by 
actual need. 
 
1) After delivery of the recombinant IL-18, it was immediately stored in aliquots at -
80°C, to avoid repeated thawing of the antigen, which could lead to degradation.  
To establish the optimum standard curve, we diluted the stock-solution of IL-18. The 
dilution range of the protein was between 250 ng/ml and 0.07 ng/ml.  
IL-18 was mixed mostly in Carbonate Buffer or 1x PBS before we prepared the 
geometric dilution series. 100 µl were added to each well according to plan. 
Additionally, of wells one row was only filled with 1x PBS or Assay Buffer, as a 
negative control.  
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2) When we established the S-ELISA system, we ordered the Module Set from Bender 
MedSystems®. Before starting with the experiments, we immediately aliquoted kit 
components and stored them at -20°C to avoid loss of bioactive human IL-18. Some 
Buffers and Solutions could be prepared by ourselves, following the description in the 
product information of Bender MedSytems®. Other reagents were not provided and 
could only be ordered.  
3) Commonly the Capture Antibody (Primary Antibody) was diluted 1:250 in 1x PBS. 
100 µl were added into each well according to plan. Immediately after pipetting, the 
microtiter plates were sealed with an adhesive film. The plates were stored overnight 
at 2°C, allowing the binding process to take place.  
4) On the following day, the plates were washed once with 400 µl Wash Buffer. After the 
washing step, the plates were tapped on absorbent pad or paper towel to remove 
excess Wash Buffer. 250 µl of Blocking Buffer were added to each well and incubated 
at room temperature for 1 hour. Washing steps were repeated two times.  
5) When we included the serum samples, we used a dilution range between 1:2 - 1:500. 
The sera were diluted in Sample Diluent. 100 µl of the diluted serum sample mixture 
was coated per well and stored overnight at 2°C. On the next day, the plates were 
washed 4 times. Plates were blocked again with 250 µl Blocking Buffer for 1 hour at 
room temperature. 
6) The Detection Antibody (Biotin-Conjugate used from Module Set) was diluted in 
Assay Buffer and dilutions differed between each experiment. Dilution ranged 
between 1:500 and 1:32000. 50 µl were added per well 1 hour at room temperature. 
Washing steps were repeated 6 times.  
7) POX-anti-goat antibody or Streptavidin-HRP was commonly prepared in Assay Buffer 
and the dilution factor was 1:4000 or 1:5000. 100 µl were added per well and 
incubated for 1 hour at room temperature. Then 6 washing steps were done. We used 
two different methods for visualizing the enzyme reaction: 
 
a) An ELISA Reaction Buffer with Phenylenediamine (see description in Materials 
Reagents - Buffers and Solutions) was prepared. 100 µl of this mixture was added to 
each well and incubated at room temperature for approximately 10 minutes. After that 
time, the color reaction was stopped by adding 50 µl 8N H2SO4. The color intensity 
can be read by the ELISA plate reader at 490 nm and 630 nm. 
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b) As an alternatively method, we also used TMB Substrate. Afterwards 6 repeats of 
washing steps, 50 µl of TMB-Substrate Solution was quickly added to all wells and 
incubated at room temperature for about 10 minutes. We avoided the direct exposure 
of the plate to intense light. The enzyme reaction was stopped by adding 50 µl TMB-
Stop Solution to all wells. The absorbance can be read at 450 nm. 
 
 
5.2.7 Mesothelin ELISA 
The following table shows the commercially available recombinant proteins inclusively the 
two antibodies that were purchased to perform a Direct ELISA or Sandwich ELISA: 
 
Recombinant Protein   
(Abnova)             
MSLN  
Recombinant Protein   
(Abnova)             
MSLN 
Anti-MSLN         
(Abnova)           
Mouse polyclonal 
antibody 
Anti-MSLN         
(Abnova)             
Rabbit polyclonal 
antibody 
Catalog ID 
H00010232-P01 
Catalog ID 
H00010232-Q01 
Catalog ID 
H00010232-A01 
Catalog ID 
H00010232-D01P 
Concentration        
0.04 µg/µl 
Concentration         
0.24 µg/µl 
Concentration      
0.05 ml  
Concentration          
1 mg/ml 
Amino acid sequence 
1 a.a.-621 a.a.          
full-length rec. protein             
with GST-tag 
Amino acid sequence 
464 a.a.-563 a.a.       
partial rec. protein    
with GST-tag 
Amino acid sequence 
464 a.a.-564 a.a.     
partial rec. protein 
with GST-tag 
Amino acid sequence 
1 a.a.-621 a.a.        
full-length             
human protein 
 
Table 5: Summary of commercially available Mesothelin proteins and antibodies 
 
Reagents: 
 Recombinant protein MSLN (Abnova; H00010232-P01) 
 Recombinant protein MSLN (Abnova; H00010232-Q01) 
 Anti-MSLN rabbit antibody (Abnova; H00010232-D01P) 
 Anti-MSLN mouse antibody (Abnova; H00010232-A01) 
 POX- anti- mouse antibody 
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 POX- anti- rabbit antibody 
 Sera dilutions 
 Assay Buffer 
 Blocking Buffer 
 Carbonate Buffer 
 1x PBS 
 0.2% PBST 
 Wash Buffer 
 ELISA Reaction Buffer with Phenylenediamine 
 8N H2 SO4   
 TMB-Substrate Solution 
 TMB-Stop Solution 
 
The following protocol describes the general procedure for MSLN-ELISA tests. It contains 
descriptions for the establishment of Direct ELISA and Sandwich ELISA, as well as operating 
the sera. The protocol is the same, but sometimes the reagents and dilution series differed by 
actual need.  
 
1) After delivery of the recombinant MSLN, it was immediately stored in aliquots at -
80°C, to avoid repeated thawing of the antigen, which could lead to degradation.  
To establish the optimum standard curve, we diluted the stock-solution of MSLN. The 
dilution range of the protein was between 250 ng/ml and 7.8 ng/ml.  
MSLN was mixed mostly in Carbonate Buffer or 1x PBS before we prepared the 
geometric dilution series. 100 µl were added to each well according to plan. 
Additionally, of wells one row was only filled with 1x PBS or Assay Buffer, as a 
negative control.  
2) When we established the S-ELISA system, we commonly diluted the Capture 
Antibody (Primary Antibody) 1:500 in 1x PBS or Assay Buffer. 100 µl were added 
into each well according to plan. Immediately after pipetting, the microtiter plates 
were sealed with an adhesive film. The plates were stored overnight at 2°C, allowing 
the binding process to take place.  
3) On the following day, the plates were washed once with 400 µl Wash Buffer. After the 
washing step, the plates were tapped on absorbent pad or paper towel to remove 
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excess Wash Buffer.  250 µl of Blocking Buffer were added to each well and 
incubated at room temperature for 1 hour. Washing steps were repeated two times.  
4) When we included the serum samples, we used a dilution range between 1:2 – 1:500. 
The sera were diluted in Sample Diluent. 100 µl of the diluted serum sample mixture 
was coated per well and stored overnight at 2°C. On the next day, the plates were 
washed 4 times. Plates were blocked again with 250 µl Blocking Buffer for 1 hour at 
room temperature. 
5) The Detection Antibody (Secondary Antibody) was diluted in Assay Buffer or 1x PBS 
and dilutions differed between each experiment. Dilutions ranged between 1:500 and 
1:32000. 50 µl were added per well for 1 hour at room temperature. Washing steps 
were repeated 6 times.  
6) POX-anti-rabbit or POX-anti-mouse antibody was commonly prepared in Assay 
Buffer and the dilution factor was always 1:4000. 100 µl were added per well and 
incubated for 1 hour at room temperature. Then 6 washing steps were done. We used 
two different methods for visualizing the enzyme reaction: 
a) An ELISA Reaction Buffer with Phenylenediamine (see description in Materials 
Reagents - Buffers and Solutions) was prepared. 100 µl of this mixture was added to 
each well and incubated at room temperature for approximately 10 minutes. After that 
time, the color reaction was stopped by adding 50 µl 8N H2SO4. The color intensity 
can be read by the ELISA plate reader at 490 nm and 630 nm. 
b) As an alternatively method, we also used TMB Substrate. Afterwards 6 repeats of 
washing steps, 50 µl of TMB-Substrate Solution was quickly added to all wells and 
incubated at room temperature for about 10 minutes. We avoided the direct exposure 
of the plate to intense light. The enzyme reaction was stopped by adding 50 µl  
TMB-Stop Solution to all wells. The absorbance can be read at 450 nm. 
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5.2.8 MSLN Dot Blot  
We aimed to test whether the two commercially available antibodies react appropriately with 
the antigen. Therefore, a Dot Blot was performed.  
   
Reagents: 
 Anti- MSLN antibodies: 
  (Abnova rabbit H00010232-D01P and Abnova mouse H00010232-A01) 
 MSLN- recombinant protein (partial protein, Abnova H00010232-Q01) 
 POX-anti-rabbit and POX-anti-mouse antibody 
 TBST 
 Whatman® Protan® Nitrocellulose Transfer Membrane 
 5% Nonfat dry milk  
 5% BSA 
 
1) The MSLN antigen stock-solution was 240 ng/µl. The 1:24 dilution was achieved by 
mixing 2µl of the antigen in 14 µl PBS. A geometric dilution series of recombinant 
CYGB protein started at 20 ng and ended at 1.25 ng by dropping the dilutions on the 
Nitrocellulose Membrane.  
2) The membrane was dried on air for a few minutes. Afterwards the membrane was 
blocked with 5% nonfat dry milk in TBST on a microplate shaker for 1 hour at room 
temperature. Then it was washed 2 times in TBST.  
3) Dilutions of Primary Antibodies were prepared in TBST/5% BSA and were added for 
1 hour at room temperature. Anti- MSLN (Abnova) was diluted 1:500 and Anti- 
MSLN (Santa Cruz) was diluted 1:1000.  
4) Next, the membrane was washed 3 times for 5 minutes in TBST. The Secondary 
Antibodies (POX-anti-rabbit and POX-anti-mouse) were diluted 1:3500 in 5% nonfat 
dry milk in TBST, added to the membranes and left on the microplate shaker for 1 
hour at room temperature. The membrane was washed 3 times for 15 minutes in 
TBST. 
5) The chemoluminescence reaction with ECL Plus reagent (GE Healthcare Amersham) 
was detected in the LUMI Imager (Boehringer Ingelheim).  
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5.2.9 Mucin 5B ELISA 
The following table shows the commercially available recombinant proteins inclusively the 
two antibodies that were needed to perform a Direct ELISA or Sandwich ELISA: 
 
Recombinant Protein    
(Abnova)                        
MUC5B 
Anti-MUC5B (Santa Cruz)   
Rabbit polyclonal antibody 
Anti-MUC5B (Abnova)      
Mouse polyclonal antibody 
Catalog ID              
H00727897-Q01 
Catalog ID                             
sc-20119 
Catalog ID             
H00727897-A01 
Concentration                     
0.17 µg/µl 
Concentration                      
200 µg/ml 
Concentration                      
0.05 ml  
Amino acid sequence          
4186 a.a.- 4296 a.a.                    
partial rec. protein                
with GST-tag 
Amino acid sequence        
raised against amino acids 
1201-1500 
Amino acid sequence          
4186 a.a.- 4296 a.a.                    
partial rec. protein                
with GST-tag 
 
Table 6: Summary of commercially available Mucin 5B protein and antibodies 
 
Reagents: 
 Recombinant protein MUC5B (Abnova; H00727897-Q01) 
 Anti-MUC5B rabbit antibody (Santa Cruz; sc-20119) 
 Anti-MUC5B mouse antibody (Abnova; H00727897-A01) 
 POX- anti- mouse antibody 
 POX- anti- rabbit antibody 
 Sera dilutions 
 Assay Buffer 
 Blocking Buffer 
 Carbonate Buffer 
 1x PBS 
 0.2% PBST 
 Wash Buffer 
 ELISA Reaction Buffer with Phenylenediamine 
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 8N H2 SO4   
 TMB-Substrate Solution 
 TMB-Stop Solution 
 
The following protocol describes the general procedure for MUC5B-ELISA tests. It contains 
descriptions for the establishment of Direct ELISA and Sandwich ELISA, as well as operating 
the sera. The protocol is the same, but sometimes the reagents and dilution series differed by 
actual need.  
 
1) After delivery of the recombinant MUC5B, it was immediately stored in aliquots at -
80°C, to avoid repeated thawing of the antigen, which could lead to degradation.  
To establish the optimum standard curve, we diluted the stock-solution of MUC5B. 
The dilution range of the protein was between 250 ng/ml and 1.25 ng/ml.  
MUC5B was mixed mostly in Carbonate Buffer or 1x PBS before we prepared the 
geometric dilution series. 100 µl were added to each well according to plan. 
Additionally, of wells one row was only filled with 1x PBS or Assay Buffer, as a 
negative control.  
2) When we established the S-ELISA system, we diluted the Capture Antibody (Primary 
Antibody) between 1:100 and 1:3000 in 1x PBS or Assay Buffer. 100 µl were added 
into each well according to plan. Immediately after pipetting, the microtiter plates 
were sealed with an adhesive film. The plates were stored overnight at 2°C, allowing 
the binding process to take place.  
3) On the following day, the plates were washed once with 400 µl Wash Buffer. After the 
washing step, the plates were tapped on absorbent pad or paper towel to remove 
excess Wash Buffer. 250 µl of Blocking Buffer were added to each well and incubated 
at room temperature for 1 hour. Washing steps were repeated two times.  
4) When we included the serum samples, we used a dilution range between 1:2 - 1:500. 
The sera were diluted in Sample Diluent. 100 µl of the diluted serum sample mixture 
was coated per well and stored overnight at 2°C. On the next day, the plates were 
washed 4 times. Plates were blocked again with 250 µl Blocking Buffer for 1 hour at 
room temperature. 
5) The Detection Antibody (Secondary Antibody) was diluted in Assay Buffer or 1x PBS 
and dilutions differed between each experiment. Dilutions ranged between 1:500 and 
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1:32000. 50 µl per well were added for 1 hour at room temperature. Washing steps 
were repeated 6 times.  
6) POX-anti-rabbit or POX-anti-mouse antibody was commonly prepared in Assay 
Buffer and the dilution factor was always 1:4000. 100 µl were added per well and 
incubated for 1 hour at room temperature. Then 6 washing steps were done. We used 
two different methods for visualizing the enzyme reaction: 
 
a) An ELISA Reaction Buffer with Phenylenediamine (see description in Materials 
Reagents - Buffers and Solutions) was prepared. 100 µl of this mixture was added to 
each well and incubated at room temperature for approximately 10 minutes. After that 
time, the color reaction was stopped by adding 50 µl 8N H2SO4. The color intensity 
can be read by the ELISA plate reader at 490 nm and 630 nm. 
b) As an alternatively method, we sometimes used TMB. Afterwards 6 repeats of 
washing steps, 50 µl of TMB-Substrate Solution was quickly added to all wells and 
incubated at room temperature for about 10 minutes. We avoided the direct exposure 
of the plate to intense light. The enzyme reaction was stopped by adding 50 µl  
TMB-Stop Solution to all wells. The absorbance can be read at 450 nm. 
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6.  Results 
6.1 Patient selection 
During surgical resection of central adenocarcinomas, relatively large amounts of cancer and 
lung tissue are resected, which are disposed by the pathologists after having taken samples for 
histology. This is a chance for thorax surgeons, protein-biochemists and molecular 
pathologists to identify new risk- and cancer-markers. So far in the unemployed tissue, one 
can find new cancer cell-specimens. Through interdisciplinary collaboration of clinical lung 
surgeons and laboratory teams, it was possible to already screen for differences between 
tumors, control tissue and establish proteome data banks. The scientists defined eight protein 
candidates, of which four can be useful for serum tests.  40 blood samples were collected and 
documented with serial numbers by the clinical partner. Patients invited for tissue or serum 
donation gave their informed consent, to ensure ethic and legal standards, like to ensure clear 
regulations of sample ownership, patient privacy and patient self determination. Generally, 
there is no way to receive information of the identity of the patients due to the way the data is 
presented in this diploma thesis. After the patient was examined by the physician, all blood 
samples were drawn before anesthesia or surgery in the clinic. For using the ELISA as a 
diagnostic strategy for human serum-samples, fresh blood was collected and delivered by the 
clinical partner. Serum was immediately prepared and stored as described in Material and 
Methods section 5.2.2, p. 31. 
 
 
6.1.1 Patient table with descriptions and staging 
The following table (Table 7) shows all patients that were used in the ELISA experiments. 
The list refers to sex, age and staging information. We counted more females than males that 
were affected by lung adenocarcinoma in our cohort. Comparing 14 female and 4 male 
patients, the mean age was 60,3 years. The control group consisted of 15 females and 5 males.  
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In order to describe the patient’s tumors, we used the following parameters: 
T… describes the size or direct extent of the primary tumor and whether it has invaded into 
the surrounding tissue. It can be specified with T0-T4. TX means no clear evidence for a 
primary tumor incidence.  
N… describes the degree of tumor spread to regional lymph nodes. It can be specified with 
N0-N3. N0 means, that the tumor is absent from regional lymph nodes and does not yet affect 
the nearby tissue. N3 means that the tumor spread to more distant or other regional lymph 
nodes. NX means no clear evidence for lymph node affection.  
G… describes the differentiation grade of the tumor tissue. It can be specified with G1-G4. 
The “low grade” G1 is well differentiated, which means that the tumor tissue is very similar 
to the original tissue. The “high grade” G4 defines poorly differentiated cells that appear very 
different than the original tissue.  
M… is another parameter of the TNM-staging system and was not included here. All patients 
were M0, because we only had patients off the time of their first surgical treatment, so the M 
was not yet known. 
 
patient number sex age   tumor staging   
      T N G 
P1 f 58 T2 N2 / 
P2 m 55 T2 N0 / 
P3 f 53 T1 N0 G1 
P4  f  70  T2   N0   G2  
P5 f 71 T1 N2 G1 
P6 f 65 T1 N2 G1 
P7 f 71 T3 N0 G1 
P8 m 72 T3 N0 / 
P9 f 67 T1  N1 G2 + G2 - G3 
P10 f 60 T2 N0 G2  
P11 f 35 TX N2 G2 
P12 f 70 T4 N2 G1 
P13 f 64 T1 N2 G1 
P15 m 64 T1 N0 G1 
P16 f 57 T1 N0 G1 
P17 f 49 T2 N0 G3 
P19 m 51 T1 N0 / 
P20 f 54 T1 N2 / 
 
Table 7: Table of all patients with information about sex, age and staging 
The table shows the correct numbering of all used patient samples in the ELISA experiments. The 
numbering was specially used after the working conditions in my experiments. So the order of 
numbering was individually arranged. Key date of the age information was 31.12. 2010.  
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According to pathologists´ examinations, all tumors were lung adenocarcinomas. During our 
study, there occurred two deviations in the diagnostic evaluation by the pathologists: 
P8 was later identified as a lung squamous epithelium carcinoma. Although we are actually 
concerned with lung adenocarcinomas, we nevertheless kept this patient sample in the 
evaluation. We were interested to observe, which ELISA results this patient serum would 
deliver.  
P14 contained small groups of high-grade atypical cell elements. After repeated and exact 
inspection of the patient preparation, the pathologists did not identify a lung adenocarcinoma. 
Because of that fact, we excluded patient number P14. 
 
Generally, we could not observe a correlation between T (tumor size) and N (lymph node 
status), as well as T and G, which indicates that the metatstatic potential of lung 
adenocarcinoma differs from tumor size and differentiation grade.  
 
 
6.2 Establishment of ELISAs against four potential lung 
tumor antigens  
The following results sections describe the detailed execution of each single ELISA test 
procedure in order to establish proper detection of the proposed tumor antigens. In order to 
accomplish this aim, we followed a clear stepwise experimental scheme: 
 
 
1. Establishment of specific ELISAs by using recombinant antigens 
This part presents the ELISA establishment phase using the recombinant proteins and 
continues with the establishment of the much more sensitive Sandwich ELISA-systems. The 
recombinant candidate proteins were additionally visualized in Dot Blots, and various 
conditions were tested to optimize the detection protocols. If necessary, recombinant forms of 
the suggested tumor marker proteins might be helpful in clarifying or overcoming potential 
masking effects occurring through the serum composition. 
In detail, here we aimed to: 
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 Define optimal coating and blocking conditions 
 Define optimal antibody concentrations (First and Secondary Antibody, etc.) 
 Control specificity by respective dilution series and blocking studies 
 Define and optimize the sensitivity threshold  
 
2. Testing of antigen-abundance in serum samples 
After the successful ELISA establishment, we turned our attention to the main objective of 
this thesis: To prove whether these antigens were available in sera from patients suffering 
from lung adenocarcinoma. The application of control sera and the inclusion of antibody 
controls (non-specific Primary IgG Antibodies, Secondary Antibodies only) in the test-system 
will be important additional parameters to define the specificity of the detection system and 
will allow a stepwise fine-tuning of this ELISA test (positive control, control sera, negative 
controls, isotype controls…). 
 
 
3. Comparison of patients´ versus control group sera  
If there were measurable significant level differences in the sera, this could be a potential 
candidate-marker, which can be prospectively used in further clinical serum-tests. At the end 
of this work phase it was determined which proteins, which antibodies, and which serum 
detection method could have the potential for a serum tumor marker. Provided that the 
methodology (antibody quality) can be established during the thesis, it will be possible to 
measure the protein concentration within two days after blood taking from the patient. 
 
 
 
 
 
 
 
 
 
 
 51 
 
6.3 Cytoglobin Detection 
6.3.1 Establishment of Direct ELISA using recombinant CYGB 
In the first experiment with Cytoglobin, we gained to establish the optimum concentrations of 
the respective antigen and antibodies. A checkerboard titration is the ideal system to 
investigate which dilution is proper for a significant signal to perform a quantitative 
evaluation of an ELISA test. As seen in Fig. 10, we worked with a CYGB-antigen dilution 
starting at 250 ng/ml and ending at 15.6 ng/ml. The antibody (Santa Cruz rabbit-anti-CYGB 
antibody) dilution range started at 1:500, and subsequent 1:1 dilutions were performed. The 
POX-labeled Secondary Antibody was diluted 1:4000. 
 
 
Fig. 10: Checkerboard titration of Cytoglobin concentrations 
Different antigen and antibody dilutions were used to establish optimal antigen and antibody 
concentrations in ELISA.  
 
As the optimum antigen concentration range we detected the range between 250 ng/ml and 
125 ng/ml with an antibody dilution of 1:500 – 1:1000. OD-values with lower concentrations 
of antigen and antibody were too low to represent a dilution that can be utilized in further 
assay experiments. The graphic shows a perfect linear decrease of the OD-values, which was 
determined with the respective concentrations and dilutions. The negative control showed that 
no unspecific process of antigen or antibody binding disturbed the binding reaction in the 
ELISA.  
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6.3.2 First Direct CYGB-ELISA with 10 serum samples 
After the successful pretest with the checkerboard titration of Cytoglobin, we immediately 
tried to test 10 serum samples. As a positive control we also included a CYGB standard series 
starting at 250 ng/ml and ending at 15.6 ng/ml which is seen in Fig. 11. The graphic shows a 
perfect continuous decrease of the values, which means that the positive control worked fine 
on the ELISA plate. 
 
 
Fig. 11: First Cytoglobin Positive Control-ELISA 
This dilution series was tested on the same ELISA plate as the serum samples.  
 
 
 
Fig. 12: First Direct Cytoglobin-Serum ELISA  
10 patient’s sera were tested in 2 dilutions. Negative controls contained no Primary Antibody. 
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In Fig. 12 we see the ELISA results of the tested serum samples (P1-P10). Two dilution steps 
of the sera, 1:10 and 1:50, were applied, to receive information about the ELISA sensitivity. 
Indeed, we detected specific positive signals versus the negative controls. We worked with a 
dilution of 1:500 of the Primary Antibody (Santa Cruz rabbit-anti-CYGB antibody) and with 
a dilution of 1:4000 of the POX-labeled Secondary Antibody (rabbit).  
Anyway, an interesting phenomenon occurred between the two serum dilutions. It was 
expected that the signals of the dilution of 1:50 would be lower than those of  1:10. 
Interestingly, with the of 1:50 dilution showing a significant higher value compared to the 
1:10 dilution. The negative control was below detection threshold, excluding unspecific 
effects of the antibodies. In further experiments we planned to use higher serum dilutions in 
order to see whether this we were able to leave the supposed plateau pahse signal intensity.  
 
 
6.3.3 Second Direct CYGB-ELISA with the same 10 serum samples 
The test arrangement of this experiment were the same as in the pretest concerning the 
dilutions of Primary Antibody and POX-labeled Secondary Antibody. The interesting 
phenomenon, that higher dilutions showed at least higher OD-values, was further analyzed. 
As a positive control we also included CYGB standard starting at 250 ng/ml and ending at 
15.6 ng/ml that can be seen in Fig. 13. The graphic shows a continuous decrease of the 
values, again indicating that the positive control worked fine on the ELISA plate. 
 
 
Fig. 13: Second Cytoglobin Positive Control-ELISA 
This dilution series was tested on the same ELISA plate beside the serum samples.  
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Fig. 14: Second Direct Cytoglobin-Serum ELISA  
10 patient’s sera were tested in 3 dilutions. Negative controls contained no Primary Antibody. 
 
In Fig. 14 the results of the same tested serum samples (P1-P10) as in Fig. 10 are presented. 
This time, three higher dilution steps of the sera (1:50, 1:250 and 1:500) were applied with 
the aim to receive more information about this observation. 
Interestingly, the phenomenon of increasing OD-values with even higher serum dilutions 
again occurred: The bar diagram of 1:50 shows a significant lower value compared to the 
dilution of 1:250 and 1:500. The negative control worked well.  
As mentioned before, the reason for the observed signal intensity phenomenon remained 
unclear. We suggested that the antibody might recognize additional antigens or organic 
material in the human sera. Another reason was that we were still working in the saturation 
region. In the following experiment we planned to use even higher serum dilutions to 
investigate this question. 
 
6.3.4 Third Direct CYGB-ELISA with the same 10 serum samples 
The test arrangement of this experiment concerning the dilutions of Primary Antibody and 
POX-labeled Secondary Antibody were the same as in the previous test. The phenomenon, 
that higher dilutions lead to increased OD-values, was further analyzed.  
As a positive control we also included a CYGB standard series starting at 250 ng/ml and 
ending at 15.6 ng/ml that can be seen in Fig. 15. The graphic shows a well done continuously 
decrease of the OD-values, which means that the positive control worked fine. 
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Fig. 15: Third Cytoglobin Positive Control-ELISA 
This dilution series was tested on the same ELISA plate beside the serum samples.  
 
 
Fig. 16: Third Direct Cytoglobin-Serum ELISA  
10 patient’s sera were tested in 3 dilutions. Negative controls contained no Primary Antibody. 
 
In Fig. 16 the ELISA results with the same tested serum samples (P1-P10) are presented. This 
time, further even higher dilution steps of the sera (1:500, 1:1000 and 1:2000) were 
performed to see the effect in this dilution range. The phenomenon of non-decreasing OD-
values again occurred with the three serum dilutions. The bar diagram of 1:500 showed a 
significant higher value compared to the 1:1000 and 1:2000 dilutions. The negative control 
worked well. As mentioned before, the reason why that phenomenon can be observed  was 
unclear. Therefore, in the following experiment we intended to explore via Western Blot the 
abundance of Cytoglobin in the sera. 
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6.3.5 Cytoglobin Western Blot with 13 serum samples 
Since we were not able to answere the question of the phenomenon of increasing bar 
diagrams, we intended to perform a Western Blot. We used patient P1-P13 to observe the 
protein bands contained in the sera after resolving them on an acrylamid SDS-gel running 
through the gel at 23V overnight. The proteins were then transferred to nitrocellulose and this 
blot was incubated, as in the ELISA, with anti-CYGB and POX-labeled anti-rabbit antibody. 
The Santa Cruz rabbit-anti-CYGB antibody was diluted 1:200 and the POX-labeled rabbit 
secondary antibody was diluted 1:3000.  
 
 
 
Fig. 17: Western Blot of patients´ sera probed with anti-CYGB antibody 
 
Fig. 17 shows the results of this analysis. The proteins have been separated by size, which is 
determined in kiloDalton (kDa), as shown on the left margin of the blot. As a control, we also 
loaded recombinant CYGB on the blot to see, to which band the antibody would bind. 
Interestingly, the Santa Cruz antibody reacted predominantly with a protein band migrating at 
approximately 43 kDa, whereas its proposed molecular weight should reside at 48 kDa 
(http://www.abnova.com/products/products_detail.asp?Catalog_id=H00114757-P01).  
This discrepancy can be explained by the presence of the GST-tag fused to the full-length 
recombinant CYGB protein. This blot proved that Cytoglobin was present in human sera and 
that the Santa Cruz antibody recognized it specifically. 
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6.3.6 Establishment of Sandwich ELISA using recombinant CYGB 
As the antibody unsed in the preliminary direct serum ELISA seemed to be quite unspecific, 
we aimed to establish a Sandwich ELISA. This was the next option to maybe receive more 
sensitive results. The CYGB  in serum might possibly be caught better with a Capture 
Antibody than by direct coating onto the wells. In the first experiment we tried to establish the 
optimum antibody and antigen coating conditions, that could be used in further test. For 
preparing a geometric dilution series, we started at 25 ng/ml and ended at 0.3 ng/ml. 
 
 
Fig. 18: Cytoglobin Sandwich ELISA 
Establishment of a Sandwich ELISA for Cytoglobin. The negative control was performed without 
antigen.  
 
Fig. 18 shows the result of the S-ELISA, where we used the Abnova mouse-anti-CYGB 
antibody as Capture Antibody, which was diluted 1:250. As a Detection Antibody we used a 
Santa Cruz rabbit-anti-CYGB antibody at a 1:500 dilution. The POX-labeled rabbit 
Secondary Antibody was diluted 1:4000. Strikingly, we observed high OD-values, but there 
was no significiant OD-value difference between the negative control wells and the 
recombinant CYGB containing wells. Therefore, we concluded that the two applied 
antibodies (Abnova and Santa Cruz) recognized each other, leading to unspecific background 
signals. Therefore, in the next experiment we intended to compare the S-ELISA and D-ELISA 
side by side on one plate with alternating Capture and Detection Antibodies, once with 
Abnova mouse and then with Santa Cruz rabbit.  
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6.3.7 Comparison of Cytglobin S-ELISA and D-ELISA 
We divided the ELISA plate into 4 rows, so that we were able to change the order of the 
Capture- and Detection Antibody, as well as to observe which one of the two different 
antibodies was better to use as a Capture- and which one was better as a Detection Antibody. 
The important expected accessory effect was to allegorize whether the S-ELISA system is 
more sensitive than the D-ELISA. 
 
 
Fig. 19: CYGB S-ELISA and D-ELISA in comparison 
This experiment was tested on one ELISA plate. The negative control was performed without antigen. 
 
In this experiment (Fig. 19), alternatively Abnova mouse anti-CYGB or Santa Cruz rabbit 
anti-CYGB antibody were used as Capture Antibodies. Both antibodies were diluted 1:250. 
For preparing a geometric dilution series, we started at 10 ng/ml and ended at 0.15 ng/ml. 
The rabbit anti-CYGB and mouse anti-CYGB antibodies were diluted 1:500. Both POX-
labeled Secondary Antibodies were diluted 1:4000 (mouse respectively rabbit).  
In the 1. S-ELISA, plates were coated with Abnova mouse-anti-CYGB antibody as the 
Capture Antibody and as a Detection Antibody we used Santa Cruz rabbit-anti-CYGB 
antibody. In this test system, we can observe that there are no significant differences between 
the dilutions and that even the negative control wells present a too high background signal. It 
is possible that the antibodies recognize each other, and therefore we got such a high 
signaling.  
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As expected, the 1. D-ELISA (we used Abnova mouse-anti-CYGB antibody) and  
2. D-ELISA (we used Santa Cruz rabbit-anti-CYGB antibody) show extremely low signals, 
because of the absence of Capture Antibodies. That confirmed our opinion that direct coating 
of the recombinant protein does not work efficiently enough.  
The wells of 2. S-ELISA were coated with Santa Cruz rabbit-anti-CYGB antibody as the 
Capture Antibody and as a Detection Antibody we used Abnova mouse-anti-CYGB antibody. 
As seen before with S-ELISA, in this interaction we can observe that there are no significant 
differences between the dilutions and that even the blank wells present a too high background 
signal. We assumed that Santa Cruz antibody is unusable as a Capture Antibody. 
In that case with our two antibody products (Abnova and Santa Cruz), we cannot define the 
optimum ELISA system, since both of them do not work very effective in combination. 
We thought the S-ELISA system would remain to be the better choice in seeking the optimum 
concentrations for the establishment. Unfortunately we cannot go on with the S-ELISA in 
combination of these two antibodies, because of the fact that the results view quite unfeasible 
bar diagrams. In summary, since the antibody from Santa Cruz turned out to be more 
ineffective as a Capture Antibody, we intended to give the Abnova product a try, because 
anyway there are the best results seen in the graphic. It is much better than the antibody from 
Santa Cruz as a Detection Antibody. Maybe the direct coating of the human sera would work 
better with the Abnova as a Detection Antibody. In the next experiment, the standard dilution 
series will be set higher, because in this experiment, we used very low antigen concentrations. 
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6.3.8 CYGB Dot Blot 
In this experiment we intended to test whether the antigen from Abnova operates 
appropriately with the antibodies from Abnova and Santa Cruz. Fig. 20 shows the result of 
this experiment. Using a geometric dilution series of CYGB, starting at 20 ng and ending at 
1.25 ng, we observed an expected decrease of the color intensity of each spot. On blot number 
1 we observed a stronger background. There seems to be a decrease of the color, but not as 
strong as in blot number 2.  Especially on blot number 2 we saw two dark spots with the 
lowest dilutions, going on with higher dilutions that lead to a decreasing color intensity. 
 
The result of the above signal row of the Dot Blot (number 1) can be interpreted that Abnova 
mouse anti-CYGB antibody might react more intensely than the Santa Cruz anti-CYGB 
antibody. Fact is that both antibodies are capable for further experiments. 
 
 
 
Fig. 20: CYGB-Dot Blot with recombinant protein and two antibodies  
The upper blot (number 1) shows the 1:500 dilution of the Abnova mouse-anti-CYGB antibody. 
The blot below (number 2) shows the 1:200 dilution of the Santa Cruz rabbit-anti-CYGB antibody. 
POX-labeled Secondary Antibody (mouse respectively rabbit) was diluted 1:3500. 
 
 
1 
2 
 61 
 
6.3.9 New Establishment of Direct ELISA with recombinant CYGB 
and Abnova mouse antibody 
After the decision to go on with the Abnova mouse-anti-CYGB antibody, we needed a 
standard curve that shows us the optimum dilution, so that we can go further with coating the 
human sera without a Capture Antibody. Fig. 21 represents the standard curve with the 
antibody dilution of 1:500. For preparing a geometric dilution series, we started at 200 ng/ml 
and ended at 12.5 ng/ml. POX-labeled Secondary Antibody (mouse) was diluted 1:4000.  
Because of the fact that this assay worked very well, we continued with the direct coating of 
human sera and chose Abnova mouse as the Detection Antibody. 
 
 
 
Fig. 21: Direct Cytoglobin ELISA 
Establishment of Direct ELISA with Abnova mouse antibody. The negative control was performed 
without antigen. 
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6.3.10 Direct CYGB-ELISA with all serum samples 
As a positive control we created a standard starting at 200 ng/ml and ending at 25 ng/ml that 
is seen in Fig. 22. The graphic shows a curve continuous decrease of the OD-values, which 
means that the positive control worked fine. 
 
 
Fig. 22: Cytoglobin Positive Control-ELISA 
This dilution series was tested on the same ELISA plate beside the serum samples.  
 
 
Fig. 23: Direct Cytoglobin-Serum ELISA with all serum samples 
Patient sera (red) and control group (green) was tested on one ELISA plate. The negative control 
(blue) was performed without serum.  
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We worked with 1:2 sera dilution. The Abnova mouse-anti-CYGB antibody was diluted 1:500 
and POX-labeled Secondary Antibody (mouse) was diluted 1:4000. The results can be seen in 
Fig. 23. It can be mentioned, that the negative control wells were significantly lower than the 
rest of the values, which tells us that the negative control did work out. Interestingly the 
control group seemed to have higher values than the patients. After these actual results, it can 
be said that we were able to establish a Cytoglobin ELISA.  
 
After calculating the average OD-values of the patients and the control sera seen, a t-test 
analysis was performed to evaluate the overall statistic relevant difference between 
Cytoglobin levels in the sera of patients versus the control group, which is also termed  
p-value. Fig. 24 shows the mean OD-values of both sample groups, and the corresponding  
p-value was 0.076. As in biological systems a p-value of 0.05 is generally considered as 
significant, which means that there is at least a 95% chance that the observed results are 
different. Our t-test result indicated that the CYGB-ELISA analysis did not reveal a 
significant higher level of Cytoglobin in the patients´ versus the control group sera. On the 
contrary, the values of the control group values seemed to be slightly but unsignificantly 
higher compared to those of the patients.  
 
 
 
Fig. 24: Average OD-values of patients´ versus control sera in the CYGB-ELISA 
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6.4 Interleukin 18 Detection 
6.4.1 Establishment of Direct ELISA using recombinant IL-18 
In the first experiment with Interleukin 18, we gained to establish the optimum concentrations 
of the antigen and antibodies. A checkerboard titration is the ideal system to investigate which 
dilution fits for a significant signal in the quantitative evaluation of an ELISA test. We 
worked with an antigen dilution starting at 250 ng/ml and ended at 15.6 ng/ml. The antibody 
(Everest Biotech goat-anti-IL-18 antibody) dilution range started at 1:500 and subsequent 1:1 
dilutions were performed. POX-labeled Secondary Antibody (goat) was diluted 1:4000. 
As seen in Fig. 25 the optimum antigen concentration range was between 250 ng/ml and  
125 ng/ml with an antibody dilution of 1:500 – 1:1000. The other values were too low to 
represent a useful dilution that can be utilized in further assay experiments. The graphic 
shows a perfect linear decrease of the values, which was estimated with these concentrations 
and dilutions. The negative control showed that no other process of the antigen or antibody 
binding disturbed the binding reaction.  
 
 
Fig. 25: Checkerboard titration of Interleukin 18 concentrations 
Different antigen and antibody dilutions were used to establish optimal antigen and antibody 
concentrations in ELISA.  
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6.4.2 First Direct Interleukin-18 ELISA with 10 serum samples 
After the successful pretest gaining optimal positive signals with the checkerboard titration of 
Interleukin 18, we tried to test 10 serum samples. As a positive control we also created an IL-
18 standard starting at 250 ng/ml and ending at 15.6 ng/ml that is seen in Fig. 26. The graphic 
shows a continuous decrease of the values, which means that the positive control worked fine 
on the ELISA plate. 
 
 
Fig. 26: First Interleukin 18 Positive Control-ELISA 
This dilution series was tested on the same ELISA plate beside the serum samples.  
 
 
 
Fig. 27: First Direct Interleukin 18-Serum ELISA  
10 patient’s sera were tested in 3 dilutions. Negative controls contained no Primary Antibody. 
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In Fig. 27 we see the ELISA results of the tested serum samples (P1-P10). We worked with 
three sera silutions (1:50, 1:250 and 1:500). The dilution of the Primary Antibody (Everest 
Biotech goat-anti-IL-18 antibody) was 1:500 and the dilution of POX-labeled Secondary 
Antibody (goat) was 1:4000. We detected positive signals versus the neagitve controls. 
Following the three different sera dilutions, we could not observe an expected decrease of 
signals. Sometimes the values seen in the graphic increased, although the dilution was higher. 
Generally the measured OD-values were too low, indicating that no significant result was 
obtained. In the next experiment, we tried to work with higher serum concentrations in order 
to gain higher signals.  
 
 
6.4.3 Second Direct Interleukin-18 ELISA with the same 10 serum 
samples 
The test arrangement of this experiment concerning the dilutions of Primary Antibody 
(Everest Biotech goat-anti-IL-18 antibody) and POX-labeled Secondary Antibody (goat) was 
the same as in the pretest. Just the dilution range of the standard curve and the dilutions of the 
sera differed in this experiment. This time, we started the dilution of the standard at 30 ng/ml 
and ended at 0.93 ng/ml that is seen in Fig. 28. The graphic shows a continuous decrease of 
the standard values, which means that the positive control worked fine on the ELISA plate. 
 
In Fig. 29 the results of the tested serum samples (P1-P10) are presented. This time three 
more concentrated dilution steps of the sera (1:10, 1:25 and 1:50) were applied to receive 
more information about the reaction. Following the three different sera dilutions, we could not 
observe an expected decrease of the OD-values although we worked with higher concentrated 
dilutions. Generally the measured OD-values were too low again, so that no significant result 
could be obtained. In the next experiment, we tried to work with even higher concentrated 
serum dilutions, to hopefully gain higher signals.  
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Fig. 28: Second Interleukin 18 Positive Control-ELISA 
This dilution series was tested on the same ELISA plate beside the serum samples.  
 
 
 
 
Fig. 29: Second Direct Interleukin 18-Serum ELISA  
10 patient’s sera were tested in 3 dilutions. Negative controls contained no Primary Antibody. 
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6.4.4 Third Direct Interleukin-18 ELISA with the same 10 serum 
samples 
The test arrangement of this experiment concerning the dilutions of Primary Antibody 
(Everest Biotech goat-anti-IL-18 antibody) and POX-labeled Secondary Antibody (goat) were 
the same as in the previous test. Just the dilution range of the IL-18 standard curve and the 
dilutions of the sera differed to the other experiment. This time, we started the dilution of the 
standard at 10 ng/ml and ended at 0.31 ng/ml which is seen in Fig. 30. The graphic shows a 
well done continuously decrease of the values, which means that the positive control worked 
fine on the ELISA plate. We detected significant positive signals versus the negative controls. 
 
In Fig. 31 the results of the tested serum samples (P1-P10) are presented. This time, three 
even more concentrated serum dilution steps (1:2, 1:5 and 1:10) were applied, to receive 
more information about the reaction. Following the three different sera dilutions, we could not 
really observe a strong increaese of the OD-values, although we worked with higher 
concentrated dilutions. Generally, the measured OD-values were very low again, but there 
seemed to be a little signal increase. From these data we concluded that the IL-18 amounts 
were very low in the sera. As a conclusion to our results with IL-18, we decided to order 
matched antibody pairs, that could be more sensitive with the human sera. Following the 
instance, described in the product information, we should be able to gain positive and 
significial results. The following experiment described the working results with the IL-18 
Module Set.  
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Fig. 30: Third Interleukin 18 Positive Control-ELISA 
This dilution series was tested on the same ELISA plate beside the serum samples.  
 
 
 
             
Fig. 31: Third Direct Interleukin 18-Serum ELISA  
10 patient’s sera were tested in 3 dilutions. Negative controls contained no Primary Antibody. 
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6.4.5 Sandwich Interleukin-18 ELISA with the same 10 serum 
samples 
The test arrangement of this experiment was now achieved with the reagents of the ordered 
Bender MedSystems® IL-18 Module Set. The dilution range of the standard curve started at 
10 ng/ml and ended at 0.62 ng/ml. The positive control can be seen in Fig. 32. The graphic 
shows a continuous decrease of the values, which means that the positive control worked fine 
on the ELISA plate. We detected positive signals versus the neagitve controls. 
 
 
Fig. 32: Interleukin 18 Positive Control-ELISA 
This dilution series was tested on the same ELISA plate beside the serum samples.  
 
 
Fig. 33: Sandwich Interleukin 18-Serum ELISA  
10 patient’s sera were tested in 3 dilutions. 
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6.4.6 Sandwich Interleukin-18 ELISA with 40 serum samples 
Again the test arrangement of this experiment was achieved with the reagents of the ordered 
Bender MedSystems® IL-18 Module Set. The dilutions of Concentrated Biotin-Conjugate and 
Concentrated Streptavidin-HRP was the same as in the pretest. The dilution range of the 
standard curve started at  5 ng/ml and ended at 0.07 ng/ml. We decided to go on with sera 
dilutions of 1:2, since working with these showing the best OD-values. The positive control 
can be seen in Fig. 34, showing continuous decrease of the values, which means that the 
positive control worked fine on the ELISA plate. We detected positive signals versus the 
negative controls. 
 
 
 
 
Fig. 34: Interleukin 18 Positive Control-ELISA 
This dilution series was tested on the same ELISA plate beside the serum samples.  
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Fig. 35: Interleukin 18-Serum ELISA with all serum samples 
Patient sera (red) and control group (green) was tested on one ELISA plate. The negative control 
(blue) was performed without serum.  
 
Fig. 35 shows the results for all serum samples. The negative control wells were compared to 
the other values very low, so the negative control was supported. Generally, it can be said that 
this established IL-18 ELISA can be used for further analyses.  
 
Further, a t-test analysis was performed to represent the overall statistic relevant difference 
between the patient and the control group. Fig. 36 shows the mean OD-values of both, the 
patient’s and the healthy control group, and the corresponding p-value was 0.000047. As 
shown in the graphic, IL-18 levels were significantly higher in the patients than in the control 
group. Therefore, we concluded that IL-18 might be a promising candidate biomarker. 
 
 
Fig. 36: Average OD-values of patients´ versus control sera in the IL-18-ELISA 
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6.5 Mesothelin Detection 
6.5.1 Establishment of the ELISA with two recombinant MSLN 
Because of the fact, that we had purchased two different Abnova MSLN products (full-length 
and partial recombinant protein), we aimed to compare the performance of these recombinant 
proteins by applying both solutions on one microtiter plate. 
To establish the optimum standard curve, we calculated the stock-solution of the MSLN 
proteins. The series started at 250 ng/ml and ended at 15.6 ng/ml. To establish the optimum 
dilution of the Primary Antibody (Abnova mouse-anti-MSLN antibody), we started the 
dilution range at 1:500, followed by 1:1000 and 1:2000. POX-labeled Secondary Antibody 
(mouse) was diluted 1:4000. 
 
 
Fig. 37: Direct Mesothelin ELISA 
Establishment of a Direct ELISA of Mesothelin with the full-length recombinant protein. The negative 
control was performed without antigen.  
 
 
Unexpectedly, we observed in that experiment (Fig. 37), that the MSLN full-length 
recombinat protein was not recognized by the antibody. The OD-values were very low. 
Although the antibody should be able to recognize all of the protein, we did not gain 
significant positive results with this combination. Therefore we tested the partial recobinant 
protein, in ELISA, whose results can be seen in Fig. 38 
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Fig. 38: Direct Mesothelin ELISA 
Establishment of a Direct ELISA of Mesothelin with the partial  recombinant protein. The negative 
control was performed without antigen.  
 
 
Here, the interaction of the partial recombinant protein with the antibody worked fine. The 
dilution series showed a perfect decrease of the OD-values. The negative control showed that 
no other process of antigen or antibody binding disturbed the binding reaction. Due to these 
results, we aimed to continue to use the partial recombinant protein in further experiments.  
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6.5.2 Direct ELISA with MSLN and 10 serum samples 
After a successful established standard series with the MSLN partial recombinant protein, we 
intended to go further with the human sera in Direct ELISA. First, only 10 sera were used in 
three different dilutions. The standard series for positive control started at 125 ng/ml and 
ended at 7.8 ng/ml. Fig. 39 shows a continuous decrease of the values, which means that the 
positive control worked fine.  
 
The sera were diluted 1:50, 1:250 and 1:500. We prepared the dilution of the Primary 
Antibody (Abnova mouse-anti-MSLN antibody) of 1:1000. POX-labeled Secondary Antibody 
(mouse) was diluted 1:4000. Fig. 40 shows the results of the direct ELISA, showing very low 
and unspecific signals. 
We concluded that it was not possible to gain signals with the sera working with direct 
ELISA. As an alternative, we tried to establish an S-ELISA in the next experiment. We 
suggested to receive better results, if we would use a Capture Antibody that could catch more 
of the protein out of the serum sample. 
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Fig. 39: First Mesothelin Positive Control-ELISA 
This dilution series was tested on the same ELISA plate beside the serum samples.  
 
 
 
 
Fig. 40: First Direct Mesothelin-Serum ELISA  
10 patient’s sera were tested in 3 dilutions. Negative controls contained no Primary Antibody. 
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6.5.3 Establishment of Sandwich ELISA with recombinant MSLN 
We intended to gain better results with an S-ELISA system, because chances are high to get 
higher OD-values, when there is a Capture Antibody coated that might catch the wanted 
protein. The Capture Antibody (Abnova rabbit-anti-MSLN antibody), was diluted it 1:250. 
The standard dilution series started at 25 ng/ml and ended at 0.39 ng/ml. The Detection 
Antibody (Abnova mouse-anti-MSLN antibody) was diluted 1:500. The POX-labeled 
Secondary Antibody (mouse) was diluted 1:4000. 
 
 
Fig. 41: Mesothelin Sandwich ELISA 
Establishment of a Sandwich ELISA of Mesothelin. The negative control was performed without 
antigen. 
 
Unfortunately we could not successfully establish a Sandwich ELISA with the available anti-
Mesothelin antibody combination. All values shown in Fig. 41 have the same levels and we 
could not observe a decrease. Even the blank wells as a negative control showed a signal, 
indicating a strong unspecific background. We concluded from these data that establishing an 
S-ELISA with MSLN was not possible with the available antibody combination.  
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6.5.4 MSLN Dot Blot  
In this experiment we intended to test whether the antigen from Abnova operates 
appropriately with the antibodies from Abnova. Using a geometric dilution series of 
recombinant MSLN, starting at 20 ng and ending at 1.25 ng, we observed the expected 
decrease of the color intensity of each spot. On blot number 1 we observed a decrease of the 
color intensity of each spot. The first one at 20 ng was the lowest dilution and showed the best 
result. The other dilutions decreased faster, which can be interpreted that the dilution of spot 
number 1 is the best one that worked. On blot number 2 we didn’t see a signal, indicating that 
the Abnova rabbit anti-MSLN did not recognize the recombinant protein. 
 
 
Fig. 42: MSLN-Dot Blot with recombinant protein and two antibodies  
The upper blot (number 1) shows the 1:500 dilution of the Abnova mouse-anti-MSLN antibody. 
The blot below (number 2) shows the 1:1000 dilution of the Abnova rabbit-anti-MSLN antibody. 
 
The result of blot number 1 can be interpreted that Abnova mouse-anti-MSLN antibody 
reacted well with the antigen. The dilution of 1:500 seems to be the best choice. The result of 
blot number 2 showed that the Abnova rabbit-anti-MSLN antibody did not function. We 
couldn’t observe any reaction with the antigen.  
In the next experiment we turned back to the D-ELISA by coating higher amounts of sera, and 
this time we used three different antibodies, to look which one worked best with the coated 
sera.  
 
1 
2 
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6.5.5 Direct MSLN-ELISA with sera and 3 different antibody 
dilutions 
Here, we aimed to test whether we could detect MSLN directly in the sera. In this experiment 
we analyzed the different performances of our three different antibodies with the sera. The 
sera were diluted 1:2 and the three antibodies were all diluted 1:500. The POX-labeled 
Secondary Antibodies (mouse respectively rabbit) were diluted 1:4000. As the antibodies did 
not recognize the recombinant MSLN, we omitted to include a standard dilution series. 
 
 
 
Fig. 43: Direct Mesothelin-Serum ELISA  
Ab X: Abbiotech rabbit-anti-MSLN antibody 
Ab Y: Abnova mouse-anti-MSLN antibody 
Ab Z: Abnova rabbit-anti-MSLN antibody 
15 patient’s sera were tested in with 3 different antibodies. Negative controls were performed without  
serum. 
 
 
As Fig. 43 shows, the Abnova rabbit antibody (Ab Z) delivered highest signals, compared to 
the other two. Unfortunately we were not able to gain a difference between patient sera and 
control group. Concerning the negative controls, the background values were definitely too 
high.  
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A t-test analysis (Fig. 44) was performed to represent the overall statistic relevant difference 
between the patients´ and the control group, yielding a p-value of 0.64. 
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Fig. 44: Average OD-values of patients´ versus control sera in the MSLN-ELISA 
 
Conclusively, although we could establish a valuable MSLN-Positive Control ELISA, we 
encountered difficulties to implement the system for the serum samples, and to establish a 
Sandwich ELISA for Mesothelin with the commercially available antibody systems. 
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6.6 Mucin 5B Detection    
6.6.1 Establishment of Direct ELISA with recombinant Mucin 5B  
To establish the optimum standard curve, we started the MUC5B standard series at 250 ng/ml 
and ended at 15.6 ng/ml. To establish the optimum dilution of the Primary Antibody (Abnova 
mouse-anti-MUC5B antibody), we started the dilution range at 1:500, followed by 1:1000, 
1:2000, 1:4000, 1:8000 and 1:16000. The POX-labeled Secondary Antibody (mouse) was 
diluted 1:4000. 
 
 
Fig. 45: Checkerboard titration of Mucin 5B concentrations 
Different antigen and antibody dilutions were used to establish optimal antigen and antibody 
concentrations in ELISA.  
 
As seen in Fig. 45, the optimum antigen concentration range was between 250 ng/ml and 125 
ng/ml with an antibody dilution of 1:500 – 1:2000. The other values were too low to 
represent a useful dilution that can be utilized in further assay experiments. The checkerboard 
titration shows a perfect continuous decrease of the values, which was estimated with these 
concentrations and dilutions. The negative control showed that no other process of the antigen 
or antibody binding disturbed the binding reaction. 
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6.6.2 First Direct MUC5B-ELISA with 10 serum samples 
We started the dilution of the standard at 125 ng/ml and ended at 7.81 ng/ml. As a positive 
control we also included MUC5B standard that is seen in Fig. 46. The graphic shows a 
continuous decrease of the values, which means that the positive control worked fine on the 
ELISA plate. We detected positive signals versus the negative controls. 
 
In Fig. 47, the results of the tested serum samples (P1-P10) are presented. Furthermore, three 
dilution steps of the sera (1:50, 1:250 and 1:500) were applied to receive more information 
about the reaction. The Primary Antibody (Abnova mouse-anti-MUC5B antibody) was diluted 
1:2000. The POX-labeled Secondary Antibody (mouse) was diluted 1:4000.  
Following the three different sera dilutions, we could not really observe the expected decrease 
of OD-values. Generally, the measured OD-values were too low, indicating that no significant 
result was was obtained. Even the negative control wells made a high signal, which told us, 
that maybe an unspecific binding took place. We suggested that very low levels of MUC5B 
were present in the sera. Therefore, in the next experiments, we tried to obtain a well working 
Sandwich ELISA. Maybe that could lead to better signals, because of using a Capture 
Antibody that catches more of the wanted protein.  
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Fig. 46: First Mucin 5B Positive Control-ELISA 
This dilution series was tested on the same ELISA plate beside the serum samples. 
 
 
 
 
 
Fig. 47: First Direct Mucin 5B-Serum ELISA  
10 patient’s sera were tested in 3 dilutions. Negative controls contained no Primary Antibody. 
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6.6.3 Establishment of Sandwich ELISA with recombinant MUC5B  
Because of the fact, that we did not gain positive results with direct serum coating, we 
intended to establish a Sandwich ELISA. Maybe the chance would be higher to catch more of 
the antigen compared to working with the D-ELISA. 
The MUC5B standard dilution series started at 20 ng/ml and ended at 2.5 ng/ml. In this 
experiment we used three different dilutions of the Capture Antibody (Santa Cruz rabbit-anti-
MUC5B antibody). The Detection Antibody (Abnova mouse-anti-MUC5B antibody) was 
diluted 1:300, 1:1500 and 1:3000. Furthermore, we used four different dilutions of the 
Detection Antibody. This antibody was diluted 1:500, 1:1000, 1:2000 and 1:4000. 
The POX-labeled Secondary Antibody (mouse) was diluted 1:4000. 
 
 
Fig. 48: Mucin 5B Sandwich ELISA 
This experiment was performed on one ELISA plate. The pink bars represent the negative controls, 
which contained no antigen. 
 
As Fig. 48 shows, we used 3 different dilutions of Capture Antibody and 4 different dilutions 
of Detection Antibody. The 1:500 dilution of the Detection Antibody lead to the highest  
OD-values. We aimed to keep this dilution in further experiments. So we have successfully 
established this Sandwich ELISA. 
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6.6.4 Sandwich MUC5B- ELISA using 2 different capture antibody 
dilutions  
In order to achieve even more specific signals with the serum samples, we worked with two 
different dilutions of the Capture Antibody (Santa Cruz rabbit-anti-MUC5B antibody). The 
Capture Antibody was diluted it 1:100 and 1:200. This time, the MUC5B standard dilution 
series started at 5 ng/ml and ended at 1.25 ng/ml. The dilution of the Detection Antibody 
(Abnova mouse-anti-MUC5B antibody) was 1:500. The POX-labeled Secondary Antibody 
(mouse) was diluted 1:4000. 
 
 
 
Fig. 49: Mucin 5B Sandwich ELISA 
Establishment of a Sandwich ELISA of Muc5B. The negative control was performed without antigen. 
 
As Fig. 49 shows, we could not really improve the S-ELISA specificity in this setting. It 
might be possible that Santa Cruz rabbit-anti-MUC5B antibody did not recognize the 
recombinant protein. The values of the negative control were too high. Maybe this strong 
background signal was occurring because of other binding processes of the Santa Cruz 
antibody.  
 
 86 
 
6.6.5 Comparison of MUC5B S-ELISA and D-ELISA with serum 
samples  
Although we could not successfully establish a Sandwich ELISA system, we tried to test the 
sera. We suggested that the antigen in the serum interacted better with the two antibodies, 
than working with the recombinant protein. We also wanted to demonstrate that the Sandwich 
ELISA system worked better than the Direct ELISA. 
In this experiment we diluted the Capture Antibody (Abnova mouse-anti-MUC5B antibody) 
1:500. The sera were diluted 1:2. The dilution of the Detection Antibody (Santa Cruz rabbit-
anti-MUC5B antibody) was 1:500. The POX-labeled Secondary Antibody (rabbit) was 
diluted 1:4000. 
 
 
 
Fig. 50: S-ELISA and D-ELISA in comparison 
This experiment was tested on one ELISA plate. The negative control was performed without antigen. 
 
As the graphic (Fig. 50) shows, we were able to demonstrate that the S-ELISA system was 
more sensitive than the D-ELISA. Because of using a Capture Antibody for coating, we 
observed that more antigen was caught in the sera. The OD-values were not high, but still 
ranged above the background control. We also observed that the OD-values of the patient sera 
were obviously a little bit higher than the sera of the control group.  
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6.6.6 Sandwich MUC5B ELISA with all sera 
We aimed to test all available sera.  
In this experiment we worked with the same dilution factors as in the pretest. The Capture 
Antibody (Abnova mouse-anti-MUC5B antibody) was diluted 1:500. The sera were diluted 
1:2. The dilution of the Detection Antibody (Santa Cruz rabbit-anti-MUC5B antibody) was 
1:500. The POX-labeled Secondary Antibody (rabbit) was diluted 1:4000. This time, we 
intended to coat all sera to receive more information about the other serum samples in 
compare.  
 
 
Fig. 51: Mucin 5B-Serum ELISA with all serum samples 
Patient sera (red) and control group (green) was tested on one ELISA plate. The negative control 
(blue) was performed without serum.  
 
In Fig. 51 shows the results of this ELISA. C9 seems to be an outlier of the control group. 
The negative control showed significant lower values, so that we could be sure, that the 
binding process worked fine.  
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Fig. 52: Average OD-values of patients´ versus control sera in the Muc5B-ELISA 
 
A t-test analysis was performed to represent the overall statistic relevant difference between 
the patient and the control group. Fig. 52 shows the mean OD-values of both, the patient’s 
and the healthy control group, and the corresponding p-value was 0.339. This means that no 
significant differences between the patients´ compared to the control group were detected. 
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6.6.7 Sandwich MUC5B ELISA with sera and 3 Detection Antibody 
dilutions 
Finally, we aimed to test whether a higher concentration of the detection antibody would lead 
to higher OD-values versus the negative control wells. 
In this experiment we worked with the same dilution factors as in the pretest, just with three 
new dilutions of the Detection Antibody. The Capture Antibody (Abnova mouse-anti-MUC5B 
antibody) was diluted 1:500. The sera were diluted 1:2. The dilutions of the Detection 
Antibody (Santa Cruz rabbit-anti-MUC5B antibody) were 1:500, 1:1000 and 1:3000. The 
POX-labeled Secondary Antibody (rabbit) was diluted 1:4000. 
 
 
Fig. 53: Sandwich Mucin 5B-Serum ELISA  
13 patient’s sera were tested with 3 different dilutions of Detection Antibody (=Det. Ab). 
The negative controls contained no serum sample. 
 
As Fig. 53 shows, we were not able to achieve a higher difference of the three antibody 
dilutions compared to the negative control wells. From these data we concluded that  
Mucin 5B levels were not significantly different in the sera of healthy versus cancer patients. 
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7.  Discussion 
In this thesis work, we aimed to draw novel conclusions from the effects seen in our 
established ELISAs. The biomarkers that we discovered in the earlier achieved surgical 
resection were chosen, because of their probable high occurrence in the human serum of 
patients suffering from lung cancer. Further, the four described antigens Cytoglobin, 
Interleukin 18, Mesothelin and Mucin 5B have been associated generally to be a candidate 
lung cancer biomarker.  
In this work we firstly tried to establish the particular ELISA for each antigen. We generally 
tested the sera in Direct ELISAs and furthermore experimented with Sandwich ELISAs as 
the second choice to reach the goal to develop a clinical blood test in order to enable an earlier 
diagnosis of lung cancer. 
 
Tumor markers in sera: 
Detection and treatment of lung adenocarcinomas at an earlier stage would highly reduce the 
death rate of this type of lung cancer. However, lung x-ray screenings and bronchial needle 
biopsies have limitations. The development of fast and reliable non-invasive tumor marker 
detection methods could improve the outcome of this disease. During this diploma thesis 
work, we tried to detect new proposed lung tumor markers in human serum by using 
recombinant proteins, serum samples and commercially available antibodies. The proposed 
biomarkers had been identified in an earlier achieved proteome analysis of surgical lung 
resections of tumor versus healthy tissue samples. The candidate proteins were chosen based 
on their highly probable occurrence in human serum of patients suffering from lung cancer. 
Here, we showed the efficiency to detect these candidates in serum samples derived from 
clinical practice. Their potential to be an important cancer biomarker was evaluated in this 
study. The final goal of this project would be the development of a clinical blood test to 
enable an earlier diagnosis of lung cancer. 
 
Specific Antigen-ELISA establishment: 
The ELISA is one of the most prominent methods to trace proteins in biological fluids in 
clinical laboratory analysis. It relies on the simple principle of a specific binding between an 
antigen and its corresponding antibody, one of which has been immobilized on a solid 
(plastic) phase. Colorimetric detection of this binding reaction by enzymatic antibody labeling 
enables a direct correlation of optical density measurements in a spectrophotometer with the 
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concentration of bound antigen. The sensitivity of this method can be very high, reaching 
ng/ml detection thresholds. Besides being a rather cheap method, the ELISA is also a fast, 
reliable and easy analytical method, as no pre-separation steps of the biological fluids is 
necessary. Further, several different antigens can be detected at once in one sample, making 
this method ideal for large scale patient screenings. Its execution can be standardized and 
performed by a working roboting workstation. Being aware that certain plasma or serum 
proteins can be unstable over longer storage time, we added the protease inhibitor trasylol to 
the samples. Throughout the whole time course of this diploma thesis, we did not observe any 
gross signal instabilities, indicating that – at least regarding our proposed tumor markers – no 
degradation phenomena occurred. This indicated that our ELISA method would be a robust 
test system, being applicable to larger cohorts of clinical patients´ blood samples deriving 
from daily blood taking routine. 
In the beginning this work we tried to establish particular detection ELISAs for each of the 
four antigens produced by recombinant protein expression technology. Various conditions 
were tested to optimize the detection protocol. As a starting point, we tested the coating 
frequency of Direct ELISA and furthermore experimented with Sandwich ELISA as the 
second choice offering a higher signal sensitivity. 
 
Cytoglobin-ELISA:  
Direct detection of recombinant Cytoglobin was immediately successful with the respective 
chosen antigen and antibody concentrations (Fig. 10). We therefore immediately tried to 
detect Cytoglobin in serum samples. Surprisingly, when trying to detect Cytoglobin in the 
sera with Direct ELISA, we obtained unusual high OD-values, although we used higher serum 
dilution steps in each experiment. The reason for that phenomenon was unclear. We suggested 
that the reaction was in the saturation region, which would mean that the Cytoglobin levels in 
the sera would be so high that even with a 1:2000 dilution we would be in the so-called 
plateau-phase (Fig. 54) of the ELISA detection range, but not in the linear range, where the 
OD-value directly correlates with increasing dilutions, which would lead to a linear decrease 
of the OD-value readings. 
A Western Blot of serum samples probed with the Santa Cruz rabbit anti-CYGB antibody 
revealed that this antibody worked quite unspecific (Fig. 17). Interestingly, a strong band 
became visible at 53 kDa, while the CYGB size was determined to be 26 kDa. Either the 
antibody shows strong cross reactivities with unrelated other serum proteins, or this 53 kDa 
band represenst a CYGB isoform or a protein containing a homologous domain. 
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Fig.54:  Different outcomes of ELISA-tests  
(adapted from www.eurogentec.com/EGT/Images/elisa1.jpg) 
 
However, based on these observations, we hoped that a Sandwich ELISA system would lead 
to more sensitive results by capturing CYGB with antibodies on the plastic surface. We 
thought that the S-ELISA system would be a better choice to seek the optimum concentrations 
for the establishment, and we compared both methods on one ELISA plate. Fig. 19 shows a 
comparison between Direct and Sandwich ELISA using all possible antibody combinations. 
We were able to show that direct coating of the antigen delivered very low signals compared 
to the signals when using the Sandwich ELISA. We could also differentiate the working 
condition between the antibodies of Santa Cruz and Abnova. Working with both, Abnova 
mouse-anti-CYGB antibody as a Capture and with Santa Cruz rabbit-anti-CYGB antibody as 
a Detection Antibody, we observed that there are no significant signal differences between the 
antigen dilutions and that even the negative control wells present a too high background 
signal. It could be possible that the antibodies bind to each other, thereby generating such high 
OD-values. Also when turning round the experimental setting the result was not significant. 
From these data we assumed that the Santa Cruz antibody is unqualified as a Capture as well 
as a Detection antibody, since the signal-background noise is not separated. Conclusively, we 
have to say that we could not define an optimal Sandwich ELISA system by applying these 
two antibodies (Abnova and Santa Cruz). 
Nonetheless, after having tested in a Dot Blot that the Abnova antibody worked at least ten 
times more sensitive than the Santa Cruz antibody (Fig. 20), we changed strategy and tried to 
perform the CYGB-test again with a Direct ELISA, applying the Abnova antibody.  
 93 
 
In principle, this ELISA-test showed significant results above background threshold level, but 
these preliminary results indicated that Cytoglobin-levels were not critically different in 
patient versus control serum samples (Fig. 23 and Fig. 24). 
 
Interleukin 18-ELISA:  
When establishing the ELISA test system for IL-18 using the recombinant antigen, we also 
immediately gained optimal OD-values. When extending the test to the serum samples, we 
had to realize that the serum-concentrations of this cytokine were very low, so that a Direct 
ELISA was not sensitive enough (Figs. 27, 29 and 31). As we could immediately dispose of a 
commercially available Sandwich test system, we were not concerned with establishment 
problems as we had encountered them with CYGB. Using this system from Bender 
MedSystems®, we were instantly able to gain reliable and positive test results for IL-18 from 
the sera even with dilutions of 1:10 (Fig. 33).  
Concerning the determination of cytokine concentration in bodily fluids, it has been noticed 
that their half-life (i.e. the time, after which half of the amount has degraded) is often very 
short. Therefore, cytokine measurements in plasma or serum can be very sensitive, especially 
when the samples have been stored over longer time periods. In the case of IL-18, we did not 
observe any instabilities of sample signals in the ELISA measurements. As all samples were 
treated in the same manner and stored over a comparable time period, we can say that this 
interleukin is a suitable serum target. Of course, the measurements performed here represent 
an actual “snapshot” of the IL-18 level in human serum samples and do not betray the cellular 
source of this inflammatory response. Therefore, the origin of IL-18 is obscure and might 
indicate (1) a strong inflammatory response of the immune system against the tumor, or (2) an 
inflammatory process of the tumor itself regulating cancer cell survival. Further, it is 
unknown whether serum levels of IL-18 are changed in other inflammatory or malignant 
diseases.  
Interestingly, our study indicated a significant elevated level of IL-18 amounts in sera of lung 
cancer patients, indicating that it might be used a valuable screening marker. We additionally 
tried to find out whether there is a correlation between the clinical parameters and the 
outcome of the ELISA. Surprisingly, we detected exceedingly high OD-values for patients´ 
sera P1, P6 and P11, whose primary tumors showed different sizes, but who all had a N2 
status. A very cautious interpretation of these data would indicate a higher incidence of serum 
IL-18 levels in patients with advanced lymph node metastatic progress of lung 
adenocarcionoma.  
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However, further extensive test series have to clarify the observed significance, also in the 
context of tumor stage and prognosis in the presence/absence of metastases.   
 
Mesothelin-ELISA: 
Establishment of a positive control test-ELISA using recombinant MSLN generated 
interesting protein-chemical questions and problems. First, we had to realize that only the 
partial recombinant protein was recognized by the antibody, though it had been generated 
against the full-length variant. Further, we revealed that the rabbit anti-MSLN antibody did 
not detect recombinant MSLN at all (Fig. 42), explaining the outcome of the test-Sandwich 
ELISA shown in Fig. 41, which did not yield specific signals. Surprisingly, this same rabbit 
anti-MSLN antibody then lead to highest OD-values in a subsequent Direct ELISA, where we 
tried to detect MSLN in the serum samples without parallel running of a positive control 
series, as it would not work with this antibody (Fig. 43). This test-system finally showed 
specific positive results with MSLN from human sera. We found a commercially available 
MSLN ELISA-test system: Mesomark ™ [35]. As this system is quite expensive, we decided 
not to order this precoated ELISA plates. 
However, we were not able to derive a significant different level of MSLN amounts in tumor 
patients versus controls. This result is interesting, as previous studies have identified MSLN 
as a tumor marker for patients with mesothelioma and ovarian cancer [39]. Our data indicate 
that either our test-system is not sensitive enough yet, or that MSLN is rather a marker for 
tumors of mesothelial rather than of ektodermal origin. 
 
Mucin 5B-ELISA: 
Regarding the establishment of a sensitive positive test-ELISA, we were immediately 
successful to see strong positive signals with the recombinant antigen (Fig. 45). 
Unfortunately, similar to MSLN, we were not able to obtain specific positive signals when 
applying the serum samples (Fig. 47) and immediately decided to switch to a Sandwich 
ELISA system. As with CYGB, we encountered detection problems with a Santa Cruz 
antibody as capturing agent (Fig. 48), though it seemed to be usable as a Detection Antibody 
(Figs. 50 and 51). Á very cautious preliminary interpretation of the serum test-ELISAs might 
indicate that there are indeed elevated MUC5B levels in the sera of lung tumor patients 
(Fig.52), though this result is not statistically significant. Therefore, a larger sample cohort 
has to be tested to extend and confirm our results. 
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Suitability of ELISAs as a serum test: 
In summary, in this thesis work we have established, which of the four potential candidate 
tumor biomarkers, which commercially available antibodies and which detection method 
could have the potential for a future serum test. Then, we aimed to draw conclusions from the 
effects seen with the patients´ sera in the previously established ELISAs.  
For all of the four potential tumor antigens we focused on, we were able to establish a 
sensitive positive control test with the recombinant proteins. When switching to test the serum 
samples, we had to envision discrepancies between the performances of the antibodies with 
recognizing the recombinant proteins versus detecting the native proteins in human sera. 
Generally, we can say that the application of a Sandwich ELISA should be the method of 
choice, as it is more sensitive than a Direct ELISA. The major drawback of this method is the 
availability of a cheap and practicable matching antibody pair system.  
From the data we retrieved with the patients´ sera, we sometimes recognized higher test-
signals, when the tumor was marked with T1/T2/T3/T4 or N1/N2. Further, sometimes, but 
not in all cases, the TX or N0 stage tumors showed lower levels of the signals. We did not 
have information from all patients concerning the G-staging, but from the data which we 
compared, there was no significant connection between the test-signals and G1/G2 and G3. 
Conclusively, at the moment, we can say that especially Interleukin 18 and maybe Mucin 5B, 
but neither Cytoglobin nor Mesothelin seem to have a potential as a critical serum marker for 
lung adenocarcinoma patients. 
 
Outlook-Summary: 
In future and ongoing collaboration with the clinical partner, our optimized serum detection 
protocol shall be verified in a prospective clinical trial using a larger patient cohort. If it is 
possible to correlate tumor staging with the amount of tumor marker in the patients´ sera, 
these results might be the basis to develop diagnostic strategies for lung tumors. Further, the 
results will be compared with the clinical parameters (tumor grade and stage, metastasis, etc.) 
to better estimate the clinical potential of the developed test system. There is a series of 
additional potential marker proteins in the lung tumor proteome database that have not been 
explored yet. These could represent additional lung cancer indicators. Only a whole panel of 
markers might probably form a useful set for detailed and meaningful tumor characterizations. 
Especially, we have identified a differential expression of IL-18 in lung adenocarcinoma 
tissue and serum. This preliminary result suggests that IL-18 could be a useful marker for the 
early diagnosis and treatment of lung cancer. 
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8.   List of abbreviations 
Ab   Antibody 
BSA   Bovine serum albumin 
C  Control group 
CF   Cystic fibrosis 
COPD  Chronic obstructive pulmonary diseases 
CT   Computer-Tomography 
CYGB  Cytoglobin 
D-ELISA  Direct ELISA 
Det. Ab.  Detection Antibody 
EDTA  Ethylenediaminetetraacetic acid 
ELISA  Enzyme-linked immunosorbent assay 
HE-staining  Haematoxylin and Eosin staining 
HRP   Horseradish peroxidase 
ICE   IL-1beta-converting enzyme 
IFN   Interferons 
Ig   Immunoglobulin 
IL-18   Interleukin 18 
MSLN  Mesothelin 
MUC5B  Mucin 5B 
neg. Co.  Negative control 
NK-cells  Natural killer cells 
OD   Optical density 
P  Patient 
PAS-staining  Periodic Acid Schiff 
PBS   Phosphate Buffered Saline 
PBST  Phosphate Buffered Saline with Tween 20 
PET   Positron emission tomography 
SD   Sample Diluent 
S-ELISA  Sandwich ELISA 
SMRP  Soluble mesothelin-related peptides 
TBS   Tris Buffered Saline 
TBST   Tris Buffered Saline with Tween 20 
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Th1   T-lymphocyte helper type 1 
TMB   3,3’,5,5’-Tetramethylbenzidine 
TNF   Tumor necrosis factors 
TR   Tandem repeats 
Tween 20 Polysorbate surfactant 
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